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Abstract 
Heart failure represents one of the leading causes of death in western civilization and is primarily 
the result of previous myocardial infarction. The fact that cardiac tissue is unable to regenerate 
after infarction led to the general belief that the heart of mammalian species is a terminally 
differentiated organ. Recently, however, evidence has emerged that the adult heart contains 
myocardial cells possessing stem cell-like properties which may have the potential to repair 
damaged tissue. The identification of factors which could activate these quiescent cardiac stem 
cells and cause them to differentiate into functional cardiomyocytes would be an important step 
towards finding new therapies for the treatment of heart diseases. 
One such factor has been proposed to be Leukemia Inhibitory Factor (LIF). LIF is a 
polyfunctional glycoprotein, showing a wide range of biological activities that include growth 
promotion and cell differentiation of various types of target cells. In previous studies, 
specifically the matrix-associated isoform of LIF (M-LIF) has been shown to positively 
influence cardiomyogenesis, in contrast to its diffusible counterpart (D-LIF). 
The aim of this diploma thesis was to investigate the potential role of LIF in cardiac 
differentiation, analyzing differences between the effect of M-LIF and D-LIF on embryonic stem 
cells, embryoid bodies, cardiac progenitor cells and cardiomyocytes, as well as the impact of 
glycosylation on biological activity. The conducted experiments reveal that both glycosylated M-
LIF and D-LIF, respectively, can be utilized as factors to trigger expansion of cardiac stem cells 
and induce differentiation into functional heart cells in vitro which may ultimately prove useful 
for cell therapy of the diseased heart. 
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Zusammenfassung 
Herzversagen stellt weltweit eine der häufigsten Todesursachen dar und ist hauptsächlich die 
Folge eines vorangegangenen Herzinfarkts. Die Tatsache, dass Herzgewebe nicht imstande ist, 
sich nach einem Infarkt zu regenerieren, führte zum allgemeinen Glauben, das Herz von 
Säugetieren sei ein ausdifferenziertes Organ. Kürzlich, jedoch, hat man im erwachsenen Herzen 
Zellen entdeckt, welche Stammzell-ähnlichen Charakter besitzen und die Fähigkeit haben 
könnten, geschädigtes Gewebe zu reparieren. Die Identifizierung von Faktoren, welche diese 
ruhenden Herzstammzellen aktivieren und zur Differenzierung zu funktionellen Herzzellen 
veranlassen können, wäre ein wichtiger Schritt in Richtung neuer Therapien von 
Herzkrankheiten. 
Ein  Faktor, der für diese Tätigkeit in Frage kommt, ist der Leukämie Inhibitions Faktor (LIF). 
LIF ist ein polyfunktionelles Glykoprotein, welches mannigfaltige biologische Aktivitäten 
aufweist, wie unter anderem Wachstumsförderung und Differenzierung verschiedenster 
Zielzellen. In vorangegangenen Studien wurde gezeigt, dass speziell die Matrix-assoziierte 
Isoform (M-LIF) sich positiv auf die Kardiomyogenese auswirkt, im Unterschied zu ihrem 
diffundierbaren Gegenstück (D-LIF). 
Ziel dieser Diplomarbeit war es, die mögliche Rolle von LIF in Bezug auf Herzzellentwicklung 
zu untersuchen, wobei Unterschiede zwischen dem Effekt von M-LIF und D-LIF auf  
embryonale Stammzellen, „Embryoid bodies“, Herzvorläuferzellen und Kardiomyozyten 
analysiert wurden, sowie der Einfluss des Glykosylierungsgrades auf die biologische Aktivität. 
In den hier durchgeführten Experimenten konnte gezeigt werden, dass sowohl glykosyliertes M-
LIF, als auch D-LIF, als Faktoren für die Expansion und gezielte Differenzierung von 
Herzvorläuferzellen eingesetzt werden können und sich damit in weiterer Folge als nützlich für 
die Zelltherapie von Herzkrankheiten erweisen könnten. 
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1 Introduction 
This diploma thesis focuses on the potential role of Leukemia Inhibitory Factor (LIF) in cardiac 
differentiation, investigating differences between the effect of its matrix-associated and 
diffusible isoforms (M-LIF and D-LIF, respectively) on embryonic stem cells, embryoid bodies, 
cardiac progenitor cells and cardiomyocytes, as well as the impact of glycosylation on biological 
activity. Based on previous data, it was anticipated that treatment with recombinantly produced 
M-LIF would lead to upregulation of cardiac markers in cardiomyocytes and contribute to 
expansion and directed differentiation of cardiac progenitor cells in vitro which may ultimately 
prove useful for cell therapy of the diseased heart. 
 
1.1 Cardiovascular disease and stem cell therapies 
Cardiovascular diseases and resulting heart failure represent one of the leading causes of death 
worldwide killing 17 million people every year (WHO, 2008). In western countries heart failure 
is primarily the result of previous myocardial infarction (Mahon et al., 1999). Existing therapy is 
extremely limited focusing on treatment of already established disease predominantly with the 
use of pharmacological agents, aiming to primarily inhibit the neurohormonal axis that results in 
excessive cardiac activation through angiotensin- or norepinephrine-dependent pathways (Itescu 
et al., 2003). For end-stage heart failure patients, the only options remaining to date are heart 
transplantation which is limited due to the extreme scarcity of donor organs (Mahon et al., 1999; 
Hognes et al., 1991) and implantation of expensive left ventricular assist devices, not proven for 
long-term use and associated with significant complications (McCarthy et al., 1991; Frazier et 
al., 1992; Oz et al., 1997). Therefore, the development of approaches that prevent heart failure 
rather than treat an already established disease is in dire need. 
One such approach is stem cell therapy, involving the clinical application of cultured stem cells. 
The identification of hematopoietic stem cells in mice heralded the use of this type of therapy 
(Till and McCulloch, 1961) and has led to the use of bone marrow derived stem cells for the 
treatment of a broad range of diseases, including breast cancer, leukemia, inflammatory bowel 
disease and osteogenesis imperfecta in humans (Kochar, 2004). Although success of this 
treatment is variable (Thomas, 1999), embryonic and somatic stem cells offer great hope for 
reversing the symptoms of many diseases and conditions such as Parkinson’s disease by 
replacing dopamine-producing cells in the brain, Type I diabetes mellitus by implanting insulin-
  7 
producing cells, and heart failure by repairing damaged heart muscle with cardiac muscle cells 
upon myocardial infarction. The following stem cell characteristics make them good candidates 
for cell-based therapies (Barker et al., 2003): 
• Potential to be harvested from patients 
• High capacity of cell proliferation in culture to obtain large numbers of cells from a 
limited source 
• Ease of manipulation to replace existing non-functional genes via gene transfer methods 
• Ability to migrate to host’s target tissues 
• Ability to integrate into host tissue and interact with surrounding tissue. 
Recently, human embryonic stem cell-derived cardiomyocytes isolated from so-called embryoid 
bodies (EBs) were transplanted into the porcine heart after induced atrioventricular block and 
could be shown to successfully function and integrate with host cells (Kehat et al., 2004). 
Somatic stem cells have also been used in cell therapy for the heart. Cardiac stem cells have 
reportedly been isolated from adult human hearts, but thus far have been shown to contribute 
only poorly to the regeneration of cardiac tissue (Beltrami et al., 2003; Urbanek et al., 2005). The 
identification of factors which could activate these quiescent cardiac stem cells in vitro and cause 
them to differentiate into functional cardiomyocytes would be an important step towards finding 
new therapies for the treatment of heart failure. Candidates for such factors include SPARC, 
BMP2, and M-LIF, which have all been found to enhance the expression of cardiac markers and 
promote cardiac differentiation in EBs (Stary et al., 2005; Behfar, 2002; Pasteiner, 2006). 
 
1.2 Heart development  
Cardiogenesis is a spatially and temporally controlled event, involving the differentiation of 
multiple heart lineages which results in the coordinated formation of the distinct tissue 
components of the heart, including the four specialized chambers, diverse structures of the 
conduction system, the endocardium, the heart valves, the coronary arterial tree, and the outflow 
tract (Harvey, 2002; Brand, 2003). In this regard, three major sources of heart cell precursors 
have been identified in the embryo: the cardiogenic mesoderm, the cardiac neural crest and the 
proepicardial organ (Laugwitz et al., 2008). 
The first source to arise is the cardiogenic mesoderm, which resembles a horseshoe-like structure 
appearing on day 7.5 in murine embryogenesis. This structure consists of two populations of 
cardiac precursor cells that contribute to different parts of the heart. The earliest population of 
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cardiac progenitors, referred to as the first heart field, originates in the anterior splanchnic 
mesoderm, gives rise to the cardiac crescent, later to the linear heart tube, and ultimately 
contributes to parts of the atrial chambers and the left ventricular region. The second cardiogenic 
region, known as the second heart field, lies anterior and dorsal to the linear heart tube and is 
derived from the pharyngeal mesoderm medial to the cardiac crescent. Cells from this second 
heart lineage are added to the developing heart tube and give rise to the outflow tract, the right 
ventricular region and the main parts of the atrial tissue (Laugwitz et al., 2008).  
The second major source of cardiac progenitors, the cardiac neural crest, migrates into the heart 
after looping of the heart tube on day 8.5 and gives rise to the vascular smooth muscle of the 
aortic arch, ductus arteriosus and the great vessels; additionally, neural crest contributes to 
essential components of the cardiac autonomic nervous system (Kirby et al., 1983; Epstein and 
Buck, 2000). At the same time cells of the third source of heart cell precursors, the proepicardial 
organ, produce the mesenchyme portion of the developing heart and the majority of epicardial 
cells (Dettman et al., 1998; Moore et al., 1999; Manner et al., 2001). Coronary vasculature might 
be partially derived from mesodermal cells in the proepicardium, although the contribution of the 
proepicardium to the endothelial lineage is still controversial (Poelmann et al., 2002). Figure 1.1 
shows a schematic summary of the processes outlined above. 
 
                   
FIGURE   1.1.     Murine heart development (Laugwitz et al., 2008). A, Contribution of the three populations of 
embryonic heart progenitors to the developing heart: Cardiogenic mesoderm (red), cardiac neural crest (purple), 
proepicardial organ (yellow). B, First (red) and second (green) heart fields and their contributions to the developing 
heart. AA, aortic arch; Ao, Aorta; HFs, head folds; IVS, interventricular septum; ML, midline; OFT, outflow tract; 
PhA, pharyngeal arches; PLA, primitive left atrium; PRA, primitive right atrium; PT, pulmonary trunk; LA, left 
atrium; RA, right atrium; LV, left ventricle; RV, right ventricle. 
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Mesoderm initially becomes instructed to adopt a cardiac fate in response to signals from 
adjacent tissues (Harvey, 2002; Srivastava and Olsen, 2000). Growth factors of the TGFß family, 
such as BMP-2 (bone morphogenetic protein) and FGF-4 (fibroblast growth factor) induce 
commitment of mesodermal cells to the cardiogenic lineage and promote the proliferation of 
specified cells, respectively (Barron et al., 2000; Lough et al., 1996; Schlange et al., 2000). Other 
candidates known to influence cardiomyogenesis are members of the Wnt family. Wnt1, Wnt3a, 
and Wnt8c have an inhibiting effect, whereas Wnt11, expressed in precardiac mesoderm, induces 
heart formation in the posterior mesoderm (Eisenberg and Eisenberg, 1999). Another candidate 
able to induce heart development is IGF-2 (insulin-like growth factor 2) which has been shown 
to lead to upregulation of the T-box protein brachyury in embryoid bodies when added in 
recombinant form (Morali et al., 2000). Brachyury – along with MESP – is amongst the earliest 
transcription factors known to direct unspecified cells into the mesoderm lineage (Kitajima et al., 
2000; Wilson and Beddington, 1997). LIM-domain-containing transcription factor islet1 (ISL1) 
is involved in the differentiation of second heart field cells (Cai et al., 2003), whereas the 
homeodomain-containing transcription factor NKX2.5 is a marker of both heart fields 
(Buckingham et al., 2005). NKX2.5 activates the target gene eHand, a basic-loop-helix (bHLH) 
transcription factor which, together with dHAND, is necessary for the looping of the heart tube 
(Harvey, 1996; Sucov, 1998). Once heart cells are terminally differentiated, markers include 
NKX2.5, GATA4, MHCα and Tropomyosin α in the case of cardiac muscle cells, NKX2.5 and 
HF-1b in the case of conduction cells, and HOXB5 in the case of endothelial cells. Figure 1.2 
depicts a brief overview of cardiac lineage differentiation with the various transcription factors 
involved. 
 
FIGURE   1.2.      Differentiation of embryonic stem cells into the cardiac lineage (Srivastava and Ivey, 2006). 
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Interestingly, remnant second heart field cells may not only be able to differentiate into many 
cell types, but also persist in the postnatal heart (Laugwitz et al., 2005). The pool of potential 
cardiac progenitor cells might be involved in continual maintenance of the heart by 
differentiating into several types of cardiac cells, including muscle, conduction and vascular 
cells, although the precise lineage potential of distinct subtypes remains to be determined 
(Srivastava and Ivey, 2006). 
 
1.3 Stem cells  
Stem cells are primal undifferentiated cells (self-renewing cells) which have the ability to 
proliferate and differentiate into cell types of various tissues in vitro and in vivo. Molecular cues 
provided by their cellular environment or niche activate transcription factors which in turn 
switch specific genetic programs on or off in a very controlled manner (Ateghang, 2006). 
Execution of the correct genetic program and therefore differentiation into specific cell types 
depends crucially on the availability of the right combination and sequence of cues (O’Shea, 
2004).  
All stem cells are characterized by three inherent abilities. First, they have the capacity of self-
renewal. This means they are capable of dividing indefinitely, producing offspring that has the 
identical potential and nature to that of the mother cell. Second, they are characterized by 
clonality, i.e. the ability to survive as a single cell and proliferate. And third, they have potency 
of differentiation, meaning they can differentiate into different types of somatic cells in the 
presence of certain lineage committing factors. Based on their developmental potential, stem 
cells can be categorized as follows: 
• Totipotent cells; these cells have the potential to give rise to all cells found in the adult 
body and any cell of the extra-embryonic tissue, such as the placenta. The only totipotent 
cells known to date are fertilized eggs and blastomeres until the morula stage. 
• Pluripotent stem cells; these cells can differentiate into any cell found in the adult body, 
but - unlike totipotent cells - cannot contribute to the formation of the extra-embryonic 
tissue. Three types of pluripotent stem cells exist (Donovan and Gearhart, 2001): 
o Embryonic stem cells (ESCs): These cells are isolated from the inner cell mass of 
the pre-implantation embryo. 
o Embryonic germ cells (EGCs): EGCs are derived from primordial germ cells 
(PGCs) isolated from the embryonic gonad.  
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o Embryonic carcinoma cells (ECCs): These cells are derived from PGCs in the 
embryonic gonad but usually are detected as components of testicular tumors in 
the adult.  
• Multipotent stem cells; these cells can only differentiate into a limited number of cell 
types. They are found in the tissue of the adult organism and are thought to be present in 
niches within most organs where they eventually replace dead or damaged cells (Ohlstein 
et al., 2004).  
 
1.3.1 Embryonic stem cells 
Embryonic stem cells (ESCs) are derived from pre-implantation embryos. Specifically, mouse 
ESCs are isolated from the inner cell mass (ICM) of the blastocyst at day 3.5 of murine 
development (Evans and Kaufman, 1981; Martin, 1981). The blastocyst is made up of three 
structures: the trophoblast, which is the layer that surrounds the blastocyst and develops into the 
embryonic membranes and placenta; the blastocoel, which is the hollow cavity inside the 
blastocyst; and the ICM, which is a group of cells at one end of the blastocoel that gives rise to 
the embryonic disk of the embryo and, later, the fetus. In order to generate an embryonic stem 
cell line, cells of the ICM are removed and replated on fresh culture plates (Figure 1.3). After 
several rounds of re-plating they can be cultured on mitotically inactivated fibroblasts or on 
feeder cell-free medium containing certain growth factors, such as LIF (Williams et al., 1988; 
Carpenter et al., 2003). In culture, they can then be propagated as a homogeneous, uncommitted 
cell population for an almost unlimited period of time without losing their pluripotency and their 
stable karyotype (Prelle et al., 2002). In the absence of feeder cells or LIF, ESCs begin to 
spontaneously differentiate in vitro, giving rise to cells of all three germ layers: ectoderm, 
mesoderm and endoderm (Guan et al., 1999; Amit et al., 2000). Both the pattern and the 
efficiency of differentiation are affected by parameters such as ESC density and media 
components (Ateghang, 2006). Directed differentiation into ectodermal, mesodermal, and 
endodermal cells, respectively, has been shown to be inducible by the addition of certain growth 
factors (Jiang et al., 2002; Muguruma et al., 2003; Romagnani et al., 2005; Schwartz et al., 2002;  
Beltrami et al., 2008).  
In vitro differentiation provides a basis for detailed studies of developmental mechanisms as well 
as for the generation of specific cell types for tissue engineering and regenerative medicine 
ttttttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttt 
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FIGURE   1.3.      Embryonic stem cell culture (Kochar, 2004). Embryonic stem cells are isolated from the inner 
cell mass of the blastocyst and can differentiate into cells of all three germinal layers.  
 
applications. However, reproducibly isolating pure differentiated cell types remains a difficult 
challenge and will be a major focus of stem cell research for years to come. 
 
1.3.2 Embryoid bodies 
Embryoid bodies (EBs) are three-dimensional embryonic stem cell aggregates that show 
development which is reminiscent of early eutherian embryogenesis (Weitzer, 2006; Figure 1.4). 
One day after aggregation in hanging drop cultures, the irregular surface smoothens to 
morphologically resemble the process of morula compaction. Between days 3 and 5, primitive 
endoderm forms, which secrets components to induce the formation of a basement membrane 
(Aumailley et al., 2000; Gao et al., 2004; Li et al., 2001; Murray and Edgar 2001; Smyth et al., 
1999). At the inner side of the primitive endoderm, ESCs develop into primitive ectoderm that 
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reorganizes into a columnar epithelium (Ikeda et al., 1999; Smyth et al., 1999) surrounding a 
central cavity, analogous to the amniotic cavity of the pre-implantation embryo. At day 4.5, 
when blastocysts implant into the uterine wall, EBs are placed on a collagen-coated surface 
which substitutes for the Reichert’s membrane in the embryo. Primitive endoderm cells then give 
rise to visceral endoderm and parietal endoderm. Primitive ectoderm develops into embryonic 
endoderm, definitive ectoderm and mesoderm, the latter of which generates rhythmically beating 
cardiomyocytes that appear between days 7 and 8 of in vitro differentiation (Doetschman et al., 
1985).  
 
FIGURE   1.4.      Schematic comparison of cells and structures between an embryoid body on day 7 and an 
early egg cylinder mouse stage embryo (Weitzer, 2006). 
 
Thus, EBs serve as a reliable model for in vitro embryogenesis, which may significantly 
contribute to the direct differentiation of embryonic and somatic stem cells towards a specific 
cell type useful for therapeutic applications and at the same time reduce animal experiments 
required for tests in the medical and pharmacological field. 
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1.3.3 Somatic stem cells  
Somatic stem cells (SSC), also referred to as adult stem cells or progenitor cells, are 
undifferentiated self-renewing cells that are found in specific compartments of specialized tissue. 
These compartments are referred to as “niches” and provide a microenvironment in which stem 
cells can reside for an indefinite period of time and produce progeny cells while self-renewing 
(Ohlstein et al., 2004). So far, SSCs have been isolated from a variety of organs including bone 
marrow, blood, skeletal muscle, brain, skin, heart, pancreas and liver (Prelle et al., 2001; 
Beltrami et al., 2007). Their primary functions are to maintain the steady state functioning of a 
cell (homeostasis) and to replace cells lost due to injury or disease (Holtzer, 1978). While it is 
questionable if all types of SSCs can be properly expanded in vitro without losing developmental 
potential, it has been shown that at least oligodendrocyte precursor cells are able to be grown 
indefinitely in culture (Tang et al., 2001).  
SSCs have long been believed to be more restricted in their developmental potential than ESCs 
and irreversibly committed to specific lineages of differentiation. For instance, it is assumed that 
SSCs residing in specific niches in the heart are limited to producing solely the cell types needed 
for this organ, namely cardiac muscle cells for contractility, cardiac conduction cells for 
coordinated electrical activity and endothelial cells for vessel formation (Figure 1.5).  
 
FIGURE   1.5.      Cardiac progenitor cells have the potential to produce at least three cell types (Srivastava 
and Ivey, 2006). 
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Recently, however, it has been proposed that SSCs could be far less limited in potency than 
previously assumed, having the ability to differentiate into unrelated cells and even cross lineage 
boundaries (Krause et al., 2002; Poulsom et al., 2002; Beltrami et al., 2007), a phenomenon 
known as “trandifferentation” (Anderson et al., 2001) or “stem cell plasticity” (Krause et al., 
2002). This plasticity has been observed not only under experimental conditions, but also in 
patients who have received bone marrow transplants (Forbes et al., 2002). 
The utilization of SSCs for medical research and cell therapy represents a practical alternative to 
that of ESCs, which is much desired due to ethical concerns. Furthermore, immunogenic 
rejection would be averted, since SSCs could be harvested from the very patient in need of 
therapy. These advantages explain the increased popularity that somatic stem cell research is 
receiving in laboratories and the general public alike. 
 
1.4 Leukemia Inhibitory Factor 
Leukemia Inhibitory Factor (LIF) is a glycoprotein belonging to the IL-6 class cytokines. It 
exhibits four α-helices (Figure 1.6) and has a molecular weight (MW) of approximately 20 kD in 
its unglycosylated form (Hinds et al., 1997). Mature LIF has three disulfide bonds and is heavily 
N-glycosylated containing six putative N-glycosylation sites in the case of LIF isolated from 
buffalo rat liver cells (rLIF). In its fully glycosylated form, rLIF has been reported to exhibit a 
ttttttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt t 
 
FIGURE   1.6.      Crystal structure of Leukemia Inhibitory Factor as published in the Protein Data Bank 
(PDB: 1LKI). (Robinson et al., 1994) 
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MW of 43 kD (Sasai et al., 1998). Thus far, LIF has been isolated from humans, mice, rats, 
sheep and pigs, showing 74 to 92% similarities in terms of amino acid sequence (Willson et al., 
1992). 
 
1.4.1 Functions and molecular mechanisms 
LIF was first discovered in the year 1987 and originally termed ES cell differentiation inhibiting 
activity (DIA), due to its ability to actively suppress stem cell differentiation (Smith and Hooper, 
1987). It was named “leukemia inhibitory factor”, because it was identified as a factor able to 
suppress leukemia in mice by inducing macrophage maturation and terminating self-renewal of 
the undifferentiated highly clonogenic murine myeloid leukemia, M1 (Gearing et al., 1987; 
Hilton et al., 1988). Now, over twenty years later, neither of these names has been found to do 
this cytokine justice, since many more biological functions have become apparent. For instance, 
LIF has been found to induce differentiation of mesenchymal cells into kidney cells (Barasch et 
al., 1999; Plisov et al., 2001; Yang et al., 2002). Neuronal functions have been identified, such as 
enhancing survival of sensory and motor neurons (Murphy et al., 1991), causing in vitro 
proliferation of multipotential human neural progenitor cells (Carpenter et al., 1999), preventing 
oligodendrocyte death in animal models of multiple sclerosis (Butzkueven, 2002), and enhancing 
migration of inflammatory macrophages to damaged neuronal tissue (Sugiura, 2000). This 
proinflammatory property is manifested by LIF’s ability to induce acute phase protein synthesis 
affecting cell recruitment into the area of damage or inflammation (Chodorowska et al., 2004).  
LIF has been reported to have multiple effects on endocrine organs or their target tissues, 
suppressing the proliferation in vitro of breast epithelial cells and breast cancer cells (Grant et al., 
2001), inhibiting the production of prolactin and growth hormone (Tomida et al., 2001), and 
reducing testosterone synthesis by Leydig cells (Mauduit et al., 2001), but, bafflingly, also 
enhancing the proliferation of primordial germ cells and spermatocyte differentiation (Piquet-
Pellorce et al., 2000; Sariola et al., 2001). In vitro studies have shown that LIF can both stimulate 
(Dazai et al., 2000) and inhibit bone formation (Reid et al., 1990). In regard to muscle action, 
LIF stimulates the proliferation of muscle satellite cells (Spangenburg et al., 2002) and can 
ameliorate muscle fiber degeneration in vivo in mdx mice lacking dystrophin (Austin et al., 
2000). Furthermore, it is a hypertrophic agent for cardiac muscle (Murata et al., 1999) and has 
been found to reduce apoptosis in cardiomyocytes (Negoro et al., 2001).  
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On the basis of this enormous body of work, it becomes clear that LIF acts on many, perhaps all, 
tissues and is a highly polyfunctional cytokine exerting potentially “adverse” functions in many 
cases. A partial explanation for this phenomenon can be found by looking into the intracellular 
signaling events triggered by LIF (Figure 1.7). LIF binds to the signal-transducing receptor 
component gp130, which is common to all IL-6 family cytokines (Taupin et al., 1998), and to the 
low-affinity LIF receptor subunit gp190, which is specific for LIF. Following heterodimerization 
of the receptors, activated Jaks phosphorylate five Tyrosines located on the intracellular domain 
of gp130. Four of these Phospho-tyrosines (P-Y 126, 173, 265 and 275) can associate with and 
phosphorylate STAT3, leading to dimerization and translocation to the nucleus, where genes for 
self-renewal and proliferation are activated. One Phospho-tyrosine (Y 118-P), however, can 
associate with SHP-2, which leads to the activation of the Ras pathway and translocation of ERK 
1/2 to the nucleus, thereby activating genes required for differentiation (Cavaleri and Schöler, 
2004). 
  
 
FIGURE   1.7.      Signal pathways induced by the IL-6 cytokine family. (Cavaleri and Schöler, 2004) 
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As previously mentioned, the receptor subunit gp130 is shared by many other cytokines, which - 
at least in part - explains the finding that LIF seems to be replaceable for almost all discovered 
functions by one cytokine or another. LIF-/- mice could be produced in expected Mendalian 
ratios and appeared to develop into healthy young adults (Metcalf, 2003). One dramatic 
abnormality, however, was that LIF-/- females were absolutely unable to become pregnant 
(Stewart et al., 1992; Escary et al., 1993). Hence, the only irreplaceable function of LIF seems to 
be implantation of the blastocyst into the uterine wall.   
Since LIF has so many different functions in such a wide array of tissues, regulating mechanisms 
must exist to modulate LIF action and prevent unwanted action in other tissues. Thus far, two 
such mechanisms have been identified: First, circulating soluble LIF receptors exist that block 
the action of any LIF in the circulation, thereby restricting action to a particular site of active LIF 
production (Layton et al., 1992). And second, negative regulators known as suppressors of 
cytokine signaling (SOCS) are produced (Starr et al., 1997). These proteins represent highly 
potent modulators of LIF signaling, with different SOCS proteins most likely acting on different 
cell types. By way of these mechanisms, LIF action can be regulated both within and between 
tissues. 
 
1.4.2 Gene structure and isoforms 
The gene coding for LIF is widely conserved among eutherian mammals and comprised of three 
exons. Three alternative sequences exist for exon 1, giving rise to three different isoforms of LIF 
upon transcription which are generated by alternative splicing (Figure 1.8): diffusible LIF (D-
LIF), matrix-associated LIF (M-LIF) and truncated LIF (T-LIF) (Voyle et al., 1999). D-LIF and 
M-LIF are secreted, whereas T-LIF remains in the cell. RNase protection studies have shown 
that these transcripts are independently regulated and are therefore likely to have distinct 
biological functions (Haines et al., 1999). 
 
FIGURE   1.8.      Schematic representation of exon splicing in the LIF gene. 
  19 
 
T-LIF is reported to have a MW of 17 kD, being considerably lighter than its counterparts. 
Unlike the first exon of murine M-LIF and D-LIF, respectively, exon 1 of T-LIF contains no 
ATG start codon. Translation is therefore initiated at the ATG codon located in exon 2, giving 
rise to a truncated version of LIF lacking a large stretch of amino-terminal amino acids found in 
murine M-LIF and D-LIF which contains a signal secretion sequence. In the mouse, the 
sequences for D-LIF and M-LIF differ from one other only in the very first amino-terminal 
amino acids, with D-LIF being merely three amino acids longer than M-LIF (Figure 1.9). D-LIF 
and M-LIF have calculated masses of 22.29 kD and 22.16 kD, respectively, including a putative 
hydrophobic leader peptide of 24 amino acids (Gearing et al., 1988) which has been proposed to 
be cleaved off in the mature versions, giving rise to proteins of approximately 20 kD in weight 
(Rathjen et al., 1990; Haines et al., 1999).  
 
 
FIGURE   1.9.      Amino-terminal sequences of murine D-LIF and M-LIF. 
 
The minor difference in sequence and possible cleavage of the putative leader peptide in both 
isoforms suggest that M-LIF and D-LIF may exert no difference in function. However, findings 
of previous studies indicate otherwise. Overexpression of M-LIF but not the D-LIF transcript 
during early mouse embryogenesis has been shown to result in gastrulation defects (Conquet et 
al., 1992). Furthermore, overexpression of M-LIF but not D-LIF has been found to rescue 
cardiomyogenesis in lif-/- embryoid bodies, rescue and promote smooth muscle cell development 
in lif-/- embryoid bodies, and promote the proliferation of erythrocytes (Weitzer et al., 
unpublished data). And in yet another study, increased proliferation and longevity of 
cardiomyocytes have been observed when grown on M-LIF overexpressing parietal endoderm 
(PE), but not when grown on D-LIF overexpressing PE (Pasteiner, 2006). Taken together, these 
results indicate a difference between the function of M-LIF and D-LIF in addition to their 
difference in localization. 
The aim of this diploma thesis was to examine the role of LIF in cardiomyogenesis, investigating 
differences between the effect of M-LIF and D-LIF on embryonic stem cells, embryoid bodies, 
cardiac progenitor cells and cardiomyocytes, as well as the impact of glycosylation on biological 
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activity. Based on the above mentioned data, it was anticipated that treatment with 
recombinantly produced M-LIF would lead to upregulation of cardiac markers in 
cardiomyocytes and contribute to expansion and directed differentiation of cardiac progenitor 
cells in vitro. 
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2 Materials 
2.1 Chemicals for molecular biology 
Acetic acid Merck, D 
Acrylamide BioRad, USA 
Agarose, Biozyme LE Biozyme, D 
Aprotinin Sigma, USA 
BCIP=5’Brom-4’Chlor-3’Indoylphosphat Diagnostic Chemicals Limited, D 
ß-Mercaptoethanol Loba Feinchemie, A 
Bis N,N’-Methylenbisacrylamide BioRad, USA 
Bromphenolblue Sigma, USA 
BSA Roth, D 
Coomassie Brilliant Blue R250 Merck, D 
Coumaric acid Sigma, USA 
Dabco Sigma, USA 
dNTPs MBI Fermentas, Lithuania 
Dimethylformamid Fluka, CH 
Dimethylsulfoxid (DMSO) Acros, B 
Dithiothreitol (DTT) Acros, B 
EDTA                                                                                     Acros, B 
Ethanol Merck, D 
Ethidiumbromide Fluka, CH 
Formaldehyde Merck, D 
Fuchsin (Pararosalinin) Sigma, USA 
Giemsa stain Sigma, USA 
Glycerin Merck, D 
Hydrochloric acid (HCl) Acros, B 
Imidazole                                                                                Sigma, USA 
Iodoacetamide Merck, D 
Leupeptin                                                                                Sigma, USA 
Methanol Merck, D 
MgCl2 MBI Fermentas, Lithuania 
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Mineral oil Sigma, USA 
Ni-NTA agarose beads Quiagen, D 
Nitrotetrazolium Blue Chloride (NBT) Fluka, CH 
PCR-buffer without MgCl2  MBI Fermentas, Lithuania 
Pepstatin A Sigma, USA 
Periodic acid Schuchardt, D 
Phenylmethansulfonylfluoride (PMSF) Flucka, CH 
Ponceau-S Sigma, USA 
Reverse Transcriptase buffer Invitrogen, USA 
SDS BioRad, USA 
Silver nitrate Merck, D 
Sodiumbicarbonate Sigma, USA 
Sodiumchloride Salinen Austria, A 
Sodiumhydrogencarbonate LifeTechnologies, USA 
Sodiumhydrogenphosphate Roth, D 
Sodiumhydroxide Merck, D 
Sodiumthiosulfate Merck, D 
Trichloracetic acid Merck D 
Tris Base LifeTechnologies, USA 
Triton X100 Sigma, USA 
Tween-20 Sigma, USA 
Urea Acros, B 
 
2.2 Chemicals for cell culture 
Ampothericin B Invitrogen, USA 
ß-Mercaptoethanol Loba, A 
D-Glucose Acros, B 
DMEM powder LifeTechnologies, USA 
DMSO (Dimethylsulfoxide) Sigma, USA 
Fetal Bovine Serum (FBS) HyClone, USA 
Fetal Bovine Serum (FBS) Gibco, USA 
Fetal Bovine Serum (FBS) Sigma, USA 
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Gelatine Difco, USA 
Geniticine (G418) Life Tech, SCO 
Glycine Applichem, D 
L-(+)-Glutamin Acros, B 
Mitomycin C Acros, B 
Penicillin G Potassiumsalt Merck, D 
Penicillin / Streptomycin GibcoBRL 
Potassium chloride Sigma, USA 
Recombinant mLIF Chemicon International 
Sf-900 SFM medium GibcoBRL 
Sodiumhydrogencarbonate LifeTechnologies, USA 
Streptomycin Sigma, USA 
 
2.3 Enzymes 
Collagenase Gibco, USA 
DNAse I, RNase free Roche, D 
Pancreatin Worthington, USA 
PNGase F NewEnglandBiolabs, USA 
RNaseOUT® LifeTechnologies, USA 
Superscript®II RNase Reverse Transcriptase LifeTechnologies, USA 
Taq DNA Polymerase MBI Fermentas, Lithuania 
Trypsin LifeTechnologies, USA 
 
2.4 Cell lines 
SNL76/7-Fibroblasts: 
These mouse fibroblasts were established by Allan Bradley. They are based on STO fibroblasts 
which were stably transfected with a neo-resistance expression vector and a LIF expression 
vector (McMahon and Bradley, 1990). 
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Embryonic stem cells: 
AB2.2 wild type isolated by Allan Bradley from the mouse strain 129Sv (Soriano et al., 1991). 
 
Cardioblast-like stem cells: 
The initial cell line was established by Wolfgang Weber. It was isolated from the heart tissue of 
neonatal HDAC1 +/- mice (neoR) and innitially co-cultured with AB2.2 embryonic stem cells in 
order to aid in survival. HDAC1 +/- mice possess a neomycin-resistance-gene, whereas AB2.2 
ESC do not. Thus, stem cells derived from the heart tissue of these mice can subsequently be 
selected for by adding G418 (Weber, 2006). 
During the course of this study, 11 subclones of this cell line were successfully established. 
 
Primary Cardiomyocytes: 
These cells were isolated from the heart tissue of day 1-2 neonatal BalbC mice.  
 
SF9 insect cells: 
The SF9 cell line was derived from pupal ovarian tissue of the fall armyworm Spodoptera 
frugiperda. 
 
2.5 Antibodies 
Table 2. 1 Antibodies used during this diploma thesis. 
Antibody Company / supplier 
Anti mLif R&D systems 
Anti 6xHIS Rockland 
 
2.6 PCR primers 
Table 2. 2 Primers used during the diploma thesis. All were ordered at VBC Genomics, Vienna. 
Primer Sequence 5' - 3' 
Number of 
nucleotides 
Tm in 
°C Cycles 
Fragment 
size 
Anf fwd cggtgtccaacacagatctg 20 50.9 55 ~200 
Anf rev tctctcagaggtgggttgac 20 48.5 55 ~200 
Bcl Xl fwd tggagtaaactgggggtcgcatcg 24 61 64 280 
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Bcl Xl rev agccaccgtcatgcccgtcagg 22 59.1 64 280 
GAPDH fwd cgt ctt cac cac cat gga ga 20 53 27-30 300 
GAPDH rev cgg cca tca cgc cac agt tt 20 60,3 27-30 300 
Islet-1 fwd atg gga gac atg ggc gat cc 20 58,1 38 ~360 
Islet-1 rev cgc agg gcg aat tcg tct cc 20 61,4 38 ~360 
MEF-2C fwd ggc cat ggt aca ccg agt aca acg agc 27 66 32 400 
MEF-2C rev ggg gat ccc tgt gtt acc tgc act tgg 27 66,8 32 400 
MHCα fwd gga aga gtg agc ggc gca tca agg 24 66,5 30 300 
MHCα rev ctg ctg gag agg tta ttc ctc g 22 54,7 30 300 
Nkx2.5 fwd tct ccg atc cat ccc act tta ttg 24 58 27-35 222 
Nkx2.5 rev ttg cgt tac gca ctc act tta atg 24 56,2 27-35 222 
 α-Tropomyosin 
fwd caagcggaggctgataagaagg 22 55 30 300 
α-Tropomyosin 
rev tgcctctctcactctcatctgc 22 55 30 300 
 
 
2.7 Expression vectors 
Vectors coding for d-lif and m-lif cDNA were kindly provided by Waltraud Pasteiner (Pasteiner, 
2006). 
 
2.8 Kits 
RNeasy® Mini Kit Qiagen, D 
QIAshredder® Homogenizer Qiagen, D 
 
2.9 Other Materials 
Amicon Ultra centrifugal filter devices                                        Millipore, USA 
Cover slips Lactan, A 
Slides La Fontaine, D 
Hyperfilm Amersham Biosciences, UK 
Immobiline Dry Strip pH 3-10 Amersham Biosciences, UK 
DNA ladder (gene ruler, 100bp, 1kb) MBI Fermentas, Lithuania 
Page RulerTM Protein Ladder MBI Fermentas, Lithuania 
Regenerated cellulose tubular membrane Roth, D 
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Sterile disposable scalpels Swann Morton, UK 
 
2.10 Inhibitors 
Aprotinin       Sigma, USA 
Leupeptin       Sigma, USA 
Pepstatin A       Sigma, USA 
Geniticine (G418)       Life Tech, SCO 
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3 Methods 
3.1 Cell culture  
All cell culture work is performed under sterile conditions.  
 
Washing glass bottles for media and solutions: 
Glass bottles are treated separately in order to avoid contact with detergents. Therefore, the 
empty glass bottles are filled with water and a small amount of hypochloride and left for several 
minutes. Then the bottles are flushed five times with tap water, and filled with MilliQ water 
(endotoxin-free, specially treated). After 1 day bottles are dried and autoclaved at 120°C, 1.4 bar 
for 20 to 30 minutes. 
 
Washing glass pipettes: 
Used pipettes are collected in vessels filled with water and hypochloride. The pipettes are 
washed with tap water for at least three hours. The vessels themselves are rinsed and refilled 
with tap water and hypochloride for desinfection. 
After washing, the pipettes are left over night in a vessel filled with MilliQ water and then dried 
at 80°C, plugged with cotton and baked in pipette boxes for eight hours at 180°C. The pipettes 
are reused exclusively for cell culture work. 
 
3.1.1 Culture of mammalian cells 
3.1.1.1 Media and solutions for mammalian cell culture 
10xPBS (Phosphate buffered saline) 
 NaCl 80 g 
 KCl 2 g 
 Na2HPO4x7H2O 10.72 g 
 KH2PO4 2 g 
Dissolve salts in 800 ml of MilliQ water and titrate to a pH-value of 7.2 with a saturated 
Na2HPO4x7H2O-solution. Fill to 1 l with MilliQ water. Sterile filtration (Nalgene Filter, Nalgene 
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Membrane; 0.22 µm pore width). Store the stock solution at room temperature in the cell culture 
room. 
 
1xPBS 
Autoclave 450 ml of MilliQ water in a 500 ml cell culture bottle. Fill the bottle to 500 ml with 50 
ml 10xPBS in the hood.  
 
100xGPS (Glutamine-Penicillin-Streptomycin) 
 NaCl 80 g 
 Penicillin 1.5 g 
 Streptomycin 2.5 g 
 L-(+)-Glutamine 14.6 g 
Dissolve substances in 500 ml MilliQ water, sterile filtration, aliquot 40 ml in 50 ml Falcons. 
Store at -20°C in the cell culture refrigerator, store at 4°C after thawing. 
 
100xß-Mercaptoethanol 
 1xPBS 200 ml 
 ß-Mercaptoethanol 144 µl 
Mix solution, sterile filtration and aliquot in 50 ml Falcons. Store at –20°C in the cell culture 
refrigerator, store at 4°C after thawing. 
 
Trypsin 
 NaCl 3.5 g 
 D-Glucose 0.5 g 
 Na2HPO4x7H2O 0.09 g 
 KCl 0.185 g 
 KH2PO4 0.12 g 
 EDTA 0.2 g 
 Trypsin 1.25 g 
 Tris Base 1.5 g 
Dissolve the chemicals in MilliQ water, titrate to pH 7.6 with concentrated HCl, fill to 500 ml 
with MilliQ water, sterilize by filtration, and aliquot 40 ml in 50 ml Falcons. Store at -20°C in 
the cell culture refrigerator, store at 4°C after thawing. 
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1% gelatine stock solution 
Solve 100 g of gelatine (Difco) in 1 l MilliQ water. Sterilize by filtration. Store at room 
temperature in the cell culture room. 
 
0.1% gelatine solution 
Autoclave 450 ml of MilliQ water in a cell culture bottle. Add 50 ml of the 1% stock solution in 
the hood and mix. 
 
Dulbecco’s Modified Eagles Medium (DMEM) 
To prepare DMEM a 5 l Erlenmayer is filled with 4.5 l of MilliQ water. Exactly one half of a 
DMEM package (Gibco) is added under stirring. Upon dissolution of the powder 18.5 g of 
sodiumbicarbonate are added. The Erlenmayer is filled to 5 l and the medium is filtered through 
sterile filters into autoclaved bottles. 4 ml of medium per bottle are extracted to perform a test for 
contaminations by incubating the medium at 37°C over night. The medium is analyzed for 
contaminations under the microscope the next day.  
 
Nutrition media for cell culture 
M10Gi:  for fibroblasts: 
 DMEM 
 10% Fetal bovine serum from Gibco 
 1x GPS 
 
M15Hi:  for ESCs and CBLSCs: 
 15% = 30 ml Fetal bovine serum from HyClone 
 1% = 2 ml GPS 
 1% = 2 ml ß-Mercaptoethanol 
           to 200 ml with DMEM 
 
M15Si:  for EBs and parietal endoderm: 
 15% = 60 ml Fetal bovine serum from Sigma 
 1% = 4 ml GPS 
 1% = 4 ml ß-Mercaptoethanol 
           to 400 ml with DMEM 
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M4Si:  for pCMCs: 
 4% =  16 ml Fetal bovine serum from Sigma 
 1% = 4 ml GPS 
 1% = 4 ml ß-Mercaptoethanol 
           to 400 ml with DMEM 
 
Freezing medium: 
 60% DMEM 
20% FBS (Gibco for fibroblasts, HyClone for ES cells, Sigma for parietal endoderm) 
 20% DMSO 
 Note: Always add DMEM first; when mixed use it immediately afterwards. 
 
3.1.1.2 Coating of cell culture plates 
Cell culture plates have to be gelatinized to serve as a matrix for the cells to adhere.  
Apply at least 2 ml of 0.1% gelatine solution per 6 well and 6 cm plate, or 3 ml per 10 cm, leave 
gelatine on plates for two hours at room temperature, then suck off the solution completely with 
a Pasteur pipette. Use the cell culture plates directly after gelatinization. 
 
3.1.1.3 Culture of SNL76/7 fibroblasts 
Stem cells can only grow on feeder cells. Our feeder cells are produced from SNL 76/7 
fibroblasts, which secret the stem cell renewal factor LIF. The cells have to be mitotically 
inactivated to serve as feeder cells. 
 
3.1.1.3.1 Thawing of SNL76/7 fibroblasts 
The cells are kept in cryotubes at –180°C in liquid nitrogen. Before thawing a vessel with water 
of 37°C, a sterile 15 ml or 50 ml Falcon tube, M10 Gi, and a 1 ml Gilson pipette have to be 
prepared. Take the cryotube out of liquid nitrogen (wear safety goggles!), thaw the cells in the 
water bath quickly until a small ice core is still left. Rinse in 70% alcohol, dry, and put it into the 
hood. Flame the cryotube and transfer the cells with the 1000 µl Gilson pipette in the prepared 
Falcon tube. Add 10 ml of M10Gi medium slowly drop by drop with a 10 ml pipette. If done too 
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quickly the cells undergo an osmotic shock and most of the cells will burst. Flame the Falcon 
tube, close it, and centrifuge at 1000 rpm, room temperature for 7 min. (Heraeus, Biofuge; 
„swing-out-buckets“). Carefully suck off medium with a Pasteur pipette. Minimize the risk to 
suck off the cell pellet by slanting the Falcon tube. Resuspend the cells in 4 ml of fresh M10Gi. 
Transfer cell suspension to a 10 cm cell culture plate (which doesn’t have to be gelatinized). 
Distribute cells equally by random movements (never in circles, this would concentrate all cell in 
the middle) and incubate at 37°C. Over night the fibroblasts adhere to the plate, and are 
confluent after a few days, meaning that the whole surface of the plate is covered with cells. 
 
3.1.1.3.2 Continuous culture of SNL76/7 fibroblasts 
The fibroblasts can be cultured on ungelatinized 10 cm cell culture plates, and have to be fed 
when the medium changes its color to yellow. When cells are confluent, they have to be split 1:5. 
 
3.1.1.3.3 Splitting of SNL76/6 fibroblasts 
The old medium is sucked off; cells are washed once with 5 ml of 1xPBS, PBS is sucked off. 
Add 1 ml trypsin with a 1000 µl Gilson pipette. Incubate the cells for 5 min at 37°C. Control the 
trypsinization status of the cells in the microscope (10x magnification). Cells should be loose and 
round because all cell contacts are destroyed. If there are still cells adhering to the plate, 
incubation time has to be extended. Care must be taken not to trypsinize for too long, since this 
may damage the cells. Add at least 4 ml of fresh M10Gi, resuspend by up- and down pipeting for 
several times. Addition of medium inactivates trypsin as soon as a ratio of 1 part trypsin to 2 
parts medium is reached. The cells are distributed onto new 10 cm plates. For example, if you 
wish to split the cells 1:3 you have to transfer a third of your volume (1.6 ml in this case) onto a 
new plate. Splitting 1:8 should be the maximum, a ratio of 1:5 is best. Fill up the plates to 8 ml 
with M10Gi. Incubate the cells at 37°C until confluence is reached. With each splitting the 
passage number is elevated by +1. 
 
3.1.1.3.4 Production of feeder cells 
Confluent plates of SNL76/7 cells are mitotically inactivated by adding 80 µl of Mitomyocin C 
to 4 ml culture medium for 3-4 hours. After carefully washing the cells with 1x PBS to remove 
remaining Mitomycin C, cells are trypsinized for 5-10 min, resuspended in 10 ml of culture 
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medium, centrifuged for 7 minutes at 1000 rpm, the supernatant is sucked off and the cell pellet 
is resuspended again in 10 ml of fresh M10Gi culture medium. The cell numbers are determined 
with the Coulter counter. Feeders in a final concentration of 1.5 – 1.75x105 cells/ml are plated 
onto gelatinized tissue culture wells – 1 ml in each well of a 24 well plate. The feeder cells are 
incubated at 37°C. The quality of the feeder cells should be examined on the next day: cells must 
cover the entire surface of the well or plate evenly. Feeder cells are able to support ES cells for 
about 2 weeks. If cells are not used immediately, the medium should be changed once it turns 
yellow or after each week in culture. 
 
Table 3. 1 Volumes of feeder cell suspension for different well sizes. 
Plate size (cm) or 
number of wells 
Cell suspension (ml) 
10 12 
6 4 
6-well 2 
24-well 1 
96-well 0.1 
 
3.1.1.3.5 Freezing of SNL76/7 fibroblasts 
Suck off medium with a Pasteur pipette and wash the cells one time with 5 ml of 1xPBS. Cover 
the cells with 0.7 ml of trypsin and incubate for 5 min at 37°C. Resuspend the loose cells in 2 ml 
of M10Gi and transfer into a 15 ml or 50 ml Falcon tube. Add 2.7 ml of 2x freezing medium 
with Gibco serum drop after drop, while permanently swirling the cell suspension in the tube. 
Transfer 1.8 ml of the cell solution with a 1000 µl Gilson pipette into each of the three cryotubes. 
Label the tubes with name of the cell line, passage, initials, amount of cells and date of freezing. 
Close cryotubes; transfer them into tightly closed polystyrene boxes for about 24h at –80°C. 
Then freeze into liquid nitrogen. Sign in the stored cells in your lab book and the stock 
registration map. 
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3.1.1.4 Culture of embryonic stem cells 
To maintain ES cells in an undifferentiated state, they have to be grown on a feeder cell layer 
that produces LIF, or on gelatinized tissue culture plates with LIF enriched medium. Our feeder 
cells originate from SNL 76/7 fibroblasts, which are able to produce the stem cell renewal factor 
LIF. 
 
3.1.1.4.1 Thawing embryonic stem cells 
ES cells should be thawed quickly at 37°C, but 10 ml of fresh M15Hi medium are added slowly 
to prevent damage of ES cells by osmotic shock. Cell suspension is then centrifuged at 1000 rpm 
for 7 minutes. Supernatant is sucked off and ESCs are resuspended in 1 ml of M15Hi medium 
taken from the pre-fed feeder layers. Plate ES cell suspension on feeder cell layer, which has 
been pre-fed with M15Hi medium for at least two hours. ES cells will attach within 24 hours – 
examine growth of ES cells the next day. 
 
3.1.1.4.2 Maintenance of embryonic stem cells 
ES cells are grown at 37°C, 5% CO2, with M15Hi culture medium, which has to be changed 
every day. Upon confluence of ES cells in a 24-well plate, they have to be pre-fed with 2 ml of 
fresh M15Hi medium 2 hours before splitting and split by trypsinization with 200 µl of trypsin 
for 20 min. Stop trypsinization by adding 1 ml of the M15Hi medium of the pre-fed feeder well. 
Cells are divided 1:3 onto pre-fed feeder cells (again two hours before splitting, the feeder cell 
medium is removed and feeder cells are pre-fed with M15Hi). 
 
3.1.1.4.3 Freezing of embryonic stem cells 
ES cells are trypsinized with 200 µl of trypsin for 20 min, then 800 µl of M15Hi medium is 
added. The cells are resuspended and transferred into a 14 ml falcon tube. To ensure retrieval of 
all ES cells, the well is washed with 800 µl of medium again and transferred into the falcon tube. 
Freezing medium is added in a 1:1 ratio very slowly, ES cells are aliquoted in cryotubes (1.8 ml 
per cryotube) and frozen at -80°C (slowly) for at least 24 hours, and then stored in liquid 
nitrogen. 
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Freezing medium: 
1 ml: 
0.6 ml DMEM 
0.2 ml Serum (the same serum as the cells were cultured with) 
3.2 ml DMSO 
 
3.1.1.5 Culture of cardioblast-like stem cells 
Cardioblast-like stem cells are thawed, maintained and frozen in the same manner as embryonic 
stem cells (see 3.1.1.4). 
 
3.1.1.5.1 Subcloning of cardioblast-like stem cells 
200 cells are seeded onto a 6-cm dish containing a feeder cell layer. 48 hours thereafter, the 
medium is exchanged and 40 µl of G418 (180 µg/ml) are added to the medium on a daily basis, 
thereby selecting for cells conferring neomycine resistance and eliminating any potential 
bystander cells.  
When colonies have reached an appreciable size, they are isolated with a Gilson pipette and 
transferred to a well of a 96-well plate containing 30 µl of trypsin. After 3 -10 minutes they are 
resuspended with 80 µl of M15Hi taken from a well of a 96-well plate containing feeder cell 
layers, which had been pre-fed 2 hours beforehand. The cell suspension is then transferred onto 
the well containing the feeder cells from which the medium had been taken. After expansion of 
the colony for a few days the cells are transferred to 24-well plates containing feeder cell layers. 
This is by definition the first passage of the newly generated subclone. 
 
3.1.1.5.2 Growth curve of cardioblast-like stem cells 
50 000 cells/well are seeded onto 6 wells of a 24-well plate containing feeder cell layers. Every 
48 hours following seeding, the cells of one well are trypsinized for 15-20 minutes and counted 
with the Coulter counter. This is repeated until all wells have been counted. The cell numbers are 
then plotted against the number of hours and a growth curve is established. 
 
The growth rate is calculated using the following formula: 
Doubling time (h) = ln2 x ∆t(h) / ln n(t2) – ln n(t1)* 
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n...number of cells 
*Values for t1 and t2 must lie within the linear portion of the graph which represents the 
exponential phase of the growth curve.  
 
3.1.1.6 Generation of embryoid bodies 
For the generation of EBs, ES cells are split 1:2 one day prior to making of EBs and trypsinized 
by adding 200 µl of trypsin for 20 minutes. After resuspension in 800 µl of M15Si, cell numbers 
are counted using the Coulter counter with a program measuring cell sizes between 10 and 20 
µm. Dilute the appropriate volume (you need 2 ml/10cm-plate) to a final cell number of 40 000 
cells/ml. 20 µl drops are put on the lid of a bacterial grade Petri dish, with water filled in the 
bottom. Drops are made with the 500 µl Eppendorf pipette which is adjusted to 25x20 µl. The 
cells in the hanging drops aggregate and form EBs, which are incubated at 37°C. On day 4.5 
after generation of EBs, they have to be plated onto gelatinized 10 cm tissue culture plates with 8 
ml of fresh M15Si culture medium. Importantly, EBs are dispersed equally on the plate by 
slightly shaking plates in two directions. 
 
 
Fig. 3. 1 Generation of embryoid bodies (Stary, 2006). 
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In general, culture medium of EBs is changed every 3rd day, leaving an aliquot of old medium to 
supply EBs with their own produced growth factors. For EB culture in M15Si medium, on day 7 
8 ml of fresh M15Si medium and 3 ml of old medium, on day 13, 16, 19 and 21, 10 ml of fresh 
and 4 ml of old medium, on day 25 and every 3 days later (if EB medium turns yellow shorten 
feeding interval), 12 ml of fresh and 5 ml of old medium are used for feeding EBs. For 
experiments with low serum the feeding protocol is changed as follows: Serum of EBs in 6 well 
plates or 24 well plates is completely removed on day 5, 6 or 7 and replaced by 4 ml (for 6 wells) 
serum free medium (M0), M0,2% Si, M1% Si, M4% Si or M10Si. Medium is changed every 3rd 
day, thus replacing half of the old medium by fresh medium. 
 
3.1.1.7 Isolation of primary cardiomyocytes from neonatal mice 
Primary cardiomyocytes were isolated from d1 and d2 wt mice (BalbC), respectively: 
• Prepare hearts from neonatal mice and place in 1x PBS. 
• Cut hearts into very small pieces, spin 2 min at 1000 rpm, remove supernatant. 
• Add 1 ml of enzyme mixture (Pancreatin/Collagenase), digest 15 min at 37°C, shaking. 
• Spin 2 min at 1000 rpm, remove supernatant, add 1 ml of fresh Pancreatin/Collagenase 
mixture. 
• Digest at 37°C, shaking 5-15 min, until a homogenous appearance is achieved. 
• spin 2 min at 1000 rpm, remove supernatant and resuspend in M4Si culture medium. 
• Pre-adsorb cardiac fibroblasts on gelatinized tissue culture plates for 2-3 h, transfer 
supernatant containing enriched cardiomyocyte population onto new gelatinized tissue 
culture plates. 
• Cultivate cardiomyocytes at 37°C, 5% CO2. 
• Renew culture medium after 24 h to remove cell debris. 
• Change medium every 3-4 days. 
 
Pancreatin/Collagenase enzyme mix: 
0.4 ml Pancreatin (Gibco) 
5 mg Collagenase (Worthington) 
9.6 ml 1x PBS 
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3.1.2 Cell culture of insect cells 
3.1.2.1 Media and solutions for insect cell culture 
SF9 thawing and adaptation medium: 
Same as culture medium, only with 20-5% FCS. 
 
SF9 culture medium:    Infection medium: 
Sf-900 medium    Sf-900 medium 
2% FBS     2% FBS 
1% P/S 
 
SF9 freezing medium:   Baculovirus freezing medium: 
20% FBS     Add 4% FBS to CM containing viral particles 
20% DMSO 
60% Sf-900 medium 
 
3.1.2.2 Sf9 cell culture 
The SF9 cell line was derived from pupal ovarian tissue of the fall armyworm Spodoptera 
frugiperda. The SF9 cell line is highly susceptible to infection with Autographa California 
nuclear polyhedrosis virus (AcNPV baculovirus), and can be used with all baculovirus 
expression vectors. Sf9 cells are commonly used to isolate and propagate recombinant 
baculoviral stocks and to produce recombinant proteins. 
 
3.1.2.2.1 Thawing and adaptation of SF9 cells 
SF9 cells are kept in liquid nitrogen for storage and stock purposes. 
The cells are quickly thawed and resuspended in SF9 II medium supplemented with 20% serum 
(Gibco), centrifugated at 1000 rpm for 5 minutes. The resulting pellet is resuspended in 5 ml of 
20% serum containing medium again, and the cells are transferred to a culture flask (xs small). 
The cells are kept in sealed flasks at 28°C. 
Once the culture has reached confluency, cells are gently scraped off the surface, collected and 
centrifugated at 1000 rpm for 5 minutes. The pellet is then resuspended in medium containing 
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15% serum, and the cells are seeded on a small culture flask. This procedure is continued with 
serum content decreasing by 5% every time the cells are split. When the serum content is below 
5% usually 2 % serum are used for maintenance of cells. 
 
3.1.2.2.2 Storage of SF9 cells 
For storage, SF9 cells are collected and resuspended in medium containing 20% serum, equal 
amounts of freezing medium (containing 20% serum and 20% DMSO) are added drop by drop, 
and the cells are stored in cryo tubes at -80°C for 24 hours. After that they can be transferred to 
liquid nitrogen. 
 
3.1.2.2.3 Infection of SF9 cells 
For expression of the desired isoforms of LIF, the cells are seeded at a correct cell number 
required for infection (4 x 107 per large flask in 20 ml medium) and the virus is added according 
to the desired MOI. Infection is achieved after 96 hours, upon which the cells are visibly bloated 
and cell lysis sets in. 
 
3.1.2.2.4 Viral plaque assay 
Materials: 
30 ml of exponential culture of SF9 cells at 5 x 105 cells/ml 
6-well plates 
1 bottle of 4% agarose gel 
1 bottle of Sf-900 medium 
0.5 ml baculovirus supernatant 
 
1. under sterile conditions dispense 2 ml of cell suspension per well. 
2. Allow cells to settle to bottom of plate and incubate, covered, at RT for 1 hour. 
3. Following 1 hour incubation of the plates at RT, observe monolayers under the inverted 
microscope to confirm cell attachment and 50% confluence. 
4. Produce an eight-log serial dilution of the harvested viral supernatant by sequentially 
diluting 0.5 ml of the previous dilution in 4.5 ml of Sf-9 medium in 15 ml Falcon tubes. 
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You should conclude with 8 tubes containg each of a 10-1 to 10-8 dilution of the original 
virus stock. 
5. Move the six well plates and the tubes of diluted virus to the hood. Label the plates, in 
columns of two, “10-3, 10-4, 10-5, 10-6, 10-7, 10-8”. 
6. Sequentially remove the supernatant from each well, discard, and immediately replace 
with 1 ml of the respective virus dilution to each duplicate well. Incubate for 1 h at RT. 
7. Melt the agarose solution in a microwave and let cool until handwarm. Quickly dispense 
30 ml of Sf-900 medium and 10 ml of the 4% agarose gel to an empty bottle and mix 
gently. 
8. Following this second 1 hour incubation, return the bottle of diluted agarose and the 6-
well plates to the hood. 
9. Melt the agarose/Sf9 medium solution and let cool until handwarm. Sequentially (from 
high to low dilution) remove the virus from the wells and replace with 2 ml of the diluted 
agarose. Work quickly to avoid desiccation of the monolayer. 
10. Allow gel to harden for 10-20 minutes before moving. 
11. Incubate at 27°C under humidified conditions (e.g. in a sealed plastic bag containing wet 
paper towels) for 4 to 10 days. 
12. Recombinant virus produces milky/gray plaques of slight contrast visible without 
staining or other detection methods. 
13. Monitor plates daily until the number of plaques counted does not change for two 
consecutive days. 
14. To determine the titer of the inoculum employed, an optimal range to count is 3 to 20 
plaques per well of a 6-well plate. The titer (pfu/ml) may be calculated with the following 
formula:  
 
Pfu/ml (of original stock) = 1/dilution factor x number of plaques x 1/(ml of inoculum/plate) 
A good high titer virus stock should lie in the range of 1 to 5 x 108  Pfu/ml. 
 
3.2 Protein purification from SF9 cells 
After infection, the cells are collected by centrifugation for 5 minutes at 1000 rpm. The 
supernatant is removed, 5 ml of 1xPBS are added, and the ce
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for 3 minutes at 1000 rpm. The 1xPBS is discarded and the cells are frozen at -80°C until further 
use.  
The cell pellet is thawed on ice and resuspended in freshly prepared lysis buffer. This is followed 
by incubation on ice for 15 minutes. The cell lysate is then mechanically disrupted in a Douncer 
(on ice), after which it is incubated on ice for 10 minutes. The lysate is then cleared by 
centrifugation at 14000 rpm, 4°C for 20 minutes. Thereafter, 10 µl of the supernatant are taken 
for analysis and the rest is distributed equally amongst four 2 ml Eppendorf tubes containing 200 
µl of Ni-NTA agarose beads (Quiagen) each, which have been equilibrated in lysis buffer. The 
beads are then rotated at 4°C for 2.5 hours. 
After loading, the beads are pelleted at 4°C, 14000 rpm for 5 minutes. 
The beads are washed three times with 500 µl of freshly prepared wash buffer by inverting the 
tube several times and subsequent pelleting of the beads at 4°C, 14000 rpm for 5 minutes. 
Elution fractions E1 and E2 are obtained by adding 200 µl of freshly prepared elution buffer I, 
followed by shaking at 800 rpm for 10 minutes and subsequent pelleting of the beads at 4°C,  
14000 rpm for 5 minutes, after which the supernatant is collected. 
Elution fractions E3 and E4 are obtained by adding 200 µl of freshly prepared elution buffer II, 
followed by shaking at 800 rpm for 10 minutes and subsequent pelleting of the beads at 4°C,  
14000 rpm for 5 minutes, after which the supernatant is collected. 
The purified protein is stored at 4°C and analyzed on an SDS polyacrylamide gel. 
 
Lysis buffer       Wash buffer 
50 mM NaH2PO4      50 mM NaH2PO4 
300 mM NaCl       300 mM NaCl 
10 mM Imidazole      10 mM Imidazole 
adjust pH to 8 using 1 M NaOH    adjust pH to 8 using 1 M NaOH 
add NP-40 at a dilution of 1:100 directly before use 
 
Elution buffer I      Elution buffer II 
50 mM NaH2PO4      50 mM NaH2PO4 
300 mM NaCl       300 mM NaCl 
50 mM Imidazole      250 mM Imidazole 
adjust pH to 8 using 1 M NaOH    adjust pH to 8 using 1 M NaOH 
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All reagents used in protein purification contain protease inhibitors Aprotinin, Leupeptin, and 
Pepstatin A at a dilution of 1:1000. 
 
If the protein is to be used for activity assays in cell culture, the sample must be freed from salts 
and imidazole prior to use. This is achieved by dialysing against a semi-permeable membrane as 
follows: 
 
Preparation of dialysis membrane: 
1. 15 cm of a regenerated cellulose tubular membrane (Roth) are rinsed with distilled water. 
2. The membrane is placed into a 50 ml Falcon tube containing 50 ml of Solution 1 and 
heated in a waterbath at 60°C for 3 h (this removes any traces of heavy metal ions). 
3. The membrane is rinsed again with distilled water. 
 
Preparation of Eppendorf tubes: 
4. Holes are burnt into the lids of Eppendorf tubes with a heated Pasteur pipette. 
5. 400 µl of sample are added per tube. 
 
Dialysis : 
6. Pieces of the membrane (~2 cm) are cut off and clamped underneath the lids of the 
prepared Eppendorf tubes, thereby covering the holes. The rest of the membrane is stored 
in 40% Ethanol. 
7. The tubes are centrifuged upside down at 1000 rpm for 1 minute to test for leakage. 
8. If no leakage is visible, the tubes are placed upside down into a beaker containing 1xPBS 
at a concentration of 1:1000 in relation to the sample amount. Otherwise, repeat step 7. 
9. The beaker is left over night at 4°C, stirring. 
 
Solution 1 : 
1 mM EDTA 
2% Sodiumhydrogencarbonate 
 
After dialysis, concentration and purity of the protein are measured with a Nanodrop device. 
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3.3 SDS polyacrylamide gel 
Isolated proteins are treated with 3x Sample buffer and separated on a denaturing SDS-
polyacrylamide gel. 
 
3x Sample buffer: 
3 ml Glycerin 
0.9 g SDS 
3.75 ml of Solution 7  
1.75 ml ddH2O 
6 mg Bromphenolblue 
 
• aliquot and store at -20°C 
• add 150 µl β−Mercaptoethanol for 850 µl sample buffer aliquot before use 
 
SDS polyacrylamide gel 
    Table 3. 2 Reagents for one mini protean gel (Biorad). 
 
 
 
 
 
 
 
 
 
 
Solution 7: 
1.5 M Tris/Cl pH 8.8 (18.17 g Tris)  
0.4% SDS (4 ml 10% SDS) 
H2O to 100 ml 
Adjust pH to 8.8 
 
solution 15% 12% 9% 6% stack 
9 5 ml 4 ml 3 ml 2 ml 250 µl 
7 2.5 ml 2.5 ml 2.5 ml 2.5 ml - 
8 - - - - 600 µl 
H2O 2.45 ml 3.45 ml 4.45 ml 5.45 ml 1.59 ml 
TEMED 5 µl 5 µl 5 µl 5 µl 5 µl 
10% APS 50 µl 50 µl 50 µl 50 µl 25 µl 
Solution 8: 
0.5 M Tris/Cl pH 6.8 (6.06 g Tris) 
0.4% SDS (4 ml 10% SDS) 
H2O to 100 ml 
Adjust pH to 6.8 
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Solution 9: 
30% Acrylamide (30 g Acrylamide) 
0.8% Bis N,N’-Methylenbisacrylamide (0.8 g Bis N,N’-Methylenbisacrylamide) 
H2O to 100 ml 
 
After polymerization of the gel, proteins and a size marker (BioRad low range or high range 
ladder) are run in a BioRad Mini Protean Gel chamber in 1x running buffer at 25 mA for 1-2 
hours, depending on the percentage of the gel.   
 
10x Running buffer: 
30 g Tris 
144 g Glycine 
10 g SDS 
H2O to 1l 
 
3.4 Coomassie staining 
Most SDS polyacrylamide gels in this study were analyzed by staining with Coomassie brilliant 
blue for 30 minutes, followed by incubation with destaining solution over night.  
Preparative gels for Mass Spectrometry analysis must be stained with fresh Coomassie staining 
solution in a glass container. Gel pieces are excised using sterile scalpels (Swann Morton) in a 
laminar flow hood. 
 
Coomassie brilliant blue      Destain 
45% (v/v) Methanol       4.5% (v/v) Methanol 
10% (v/v) Acetic acid      10% (v/v) Acetic acid 
0.4% (w/v) Coomassie Brilliant Blue 
 
3.5 Silver staining 
In some cases, SDS polyacrylamide gels were silver stained for increased signal sensitivity:  
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First, the gel is fixed for 20 minutes with fixer solution. Then the gel is washed for 10 minutes 
with washing solution and incubated in MilliQ water over night. On the following day, the gel is 
sensitized for 1 minute with Sensitizing solution, washed twice with MilliQ water for 1 minute 
each and incubated with Silver solution for 20 minutes at 4°C. The gel is then washed twice with 
MilliQ water for 1 minute each and developed for 5-10 minutes in Developing solution. Color 
development is terminated with Stop solution, which is added three times for one minute each. 
All steps are carried out on a shaker in the hood. 
 
Fixer solution        Sensitizing solution 
50 ml Methanol       0.02 g Sodium thiosulfate       
5 ml Acetic acid       to 100 ml with MilliQ water 
45 ml MilliQ water 
 
Washing solution       Silver solution 
50 ml Methanol       0.1 g Silver nitrate                
50 ml MilliQ water       to 100 ml with MilliQ water 
  
Developing solution       Stop solution 
2 g Sodium carbonate       5 ml Acetic Acid           
40 µl 35% formaldehyde      to 100 ml with MilliQ water 
to 100 ml with MilliQ water 
 
3.6 Western Blot analysis 
Proteins separated by a SDS-Polyacrylamide gel are transferred to a nitrocellulose membrane 
(Schleicher and Schuell) using a BioRad semi-dry transfer cell. The blot consists of (from the 
bottom upwards): 6 layers of Whatman paper the same size as the gel, one nitrocellulose 
membrane the same size as the gel, the gel, and 6 layers of Whatman paper the same size as the 
gel. All components are soaked with blotting buffer.  
Air bubbles are removed by applying pressure with a Falcon tube. Blotting is carried out at 16 V 
for 1 hour. 
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10x Blotting buffer: 
0.48 M Tris  
0.4 M Glycine 
ddH20 
Adjust pH to 9.1 
 
After blotting the protein is stained with Ponceau-S for 5 minutes and rinsed with water to assess 
transfer and to visualize the protein ladder which can then be marked with a pen. 
 
Ponceau-S         
100 mg Ponceau-S        
100 ml 1% glacial acetic acid   
     
Antibody incubation and development of the blot: 
After blotting, the membrane is blocked with blocking solution for 1 hour. This is followed by 
three wash steps with 1xTBS/0.1% Tween for 5 minutes each and incubation over night with 
primary antibody solution. On the following day, the membrane is washed three times with 
1xTBS/0.1% Tween for 5 minutes each and incubated with the secondary antibody solution for 1 
hour. The membrane is then washed three times with 1xTBS/0.1% Tween for 5 minutes each. 
 
• Detection depends on used secondary antibody: 
o for an  AP conjugated antibody the blot is incubated with AP buffer for 5 minutes 
o the blot is incubated with 10 ml of AP buffer with 33 µl of NBT (added first) and 
66 µl of BCIP (add second) 
o the blot is incubated in the dark until bands become visible (5-60 minutes), the 
reaction is  stopped by removing AP buffer and washing with water 
 
o for HRP conjugated antibody, 1 ml of ECL solution is mixed with 3 µl of H2O2 
and the blot is incubated with this solution for 1 minute 
o detection by exposure to a film for 5-60 minutes (Hyperfilm, Amersham) 
o the film is developed in a AGFA curix60 machine 
 
Blocking solution: 
5% dry milk powder (low fat) 
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dissolve in 1xTBS/0.1% Tween 
 
Primary antibody  solution     Secondary antibody  solution 
5% BSA       5% dry milk powder (low fat) 
dissolve in 1xTBS/0.1% Tween    dissolve in 1xTBS/0.1% Tween                                                                                   
desired amount of primary antibody    desired amount of secondary antibody  
 
NBT        AP buffer: 
75 mg NBT       100 mM Tris/Cl PH 9.5 
700 µl Dimethylformamid     100 mM NaCl 
300 µl H2O       50 mM MgCl2 
 
BCIP        ECL stock solution: 
50 mg BCIP       dilute 20 ml 1MTris in 200 ml H2O  
1 ml Dimethylformamid     add 0.5 ml p-Coumaric acid 
        add 1 ml Luminol 
 
Table 3. 2 Antibodies used for Western blotting. 
Primary antibody Secondary antibody 
α LIF  1:500 anti goat AP 1:10 000 
α 6xHIS 1:15 000 anti rabbit HRP 1:30 000 
 
3.7 2-D gel electrophoresis 
For 2-D-gel electrophoreses 50 µg of protein* are solved in 250 µl of Sample buffer and rotated 
for at least 30 minutes at room temperature, after which the protein sample is loaded on the 
Immobiline Dry Strip pH 3-10 (Amersham) as follows: the sample has to be carefully dropped in 
the IPGphor ceramic strip holder (13 cm, Amersham) and the strip placed on the sample with the 
positive direction on the pointed end. After that the strip has to be covered with 800 µl of 
mineral oil. 
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*using cell CM makes serum starvation necessary to avoid albumin spots which often overlay 
other spots. 
 
Isoelectric focusing 
Isoelectric focusing is performed on IPGphor (Amersham) under following conditions: 
Table 3. 3 Program for isoelectric focusing. 
Time Voltage 
10 hours, 20°C rehydration - 
30 min 200 V 
45 min 500 V 
2 h gradient from 500 V – 3500 V 
6 h 3500 V 
4 h 100 V 
 
After isoelectric focusing of the sample the gel strip is washed for 15 min with Equilibration 
buffer 1, and 15 min with Equilibration buffer 2. Then place the strip on a SDS-page gel and 
cover it with agarose sealing solution. The gel strip replaces the stack gel. Gel run: 200, V 3.5 h. 
When the gel run is finished, the gel can be used for Coomassie staining (see 3.4), Silver staining 
(see 3.5) or Western blot analysis (see 3.6). 
 
Sample buffer (Sprenger et al.; 2004): 
7 M Urea 
2 M Tris-HCl 
4 % Triton X-100 
2 v/v% Carrier Ampholyte pH 3-10 
20 mM Tris-base 
55 mM DTT 
0.003 % Bromphenolblau 
store in 250 µl aliquots at -20°C 
 
 
Agarose sealing solution: 
0.5 v/v% Agarose 
Equilibration buffer 1 & 2: 
50 mM Tris/HCl pH 8.8 
6 M Urea 
30 % Glycerin 
2 % SDS 
0.002 % Bromphenolblau 
buffer 1: 6 ml + 150 µg Iodoacetamid 
buffer 2: 10 ml + 100 µg DTT 
Idoacetamid and DTT always have to 
be added immediately before use 
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0.002 % Bomphenolblau 
solved in 1x Running buffer (see SDS polyacrylamide gel) 
 
3.8 Glycoprotein detection 
3.8.1 Periodic acid-Schiff stain  
Periodic acid-Schiff (PAS) is a staining method mostly used in histology and pathology. This 
method is primarily used to identify glycogen in tissues. The reaction of periodic acid selectively 
oxidizes the glucose residues, creates aldehydes that react with the Schiff’s reagent and creates a 
purple magenta color. A suitable basic stain is often used as a counterstain.  
Following SDS polyacrylamide gel electrophoresis, samples can be stained directly for the 
presence of carbohydrates (Van-Seuningen and Davril, 1992): 
Table 3. 5 Periodic acid-Schiff stain procedure. 
Reagent Incubation time 
20% Trichloracetic acid 5 min 
ddH2O 5 min 
0.7% periodic acid + 5% acetic acid 10 min 
ddH2O 2 min 
ddH2O 2 min 
Schiff’s reagent 10 min 
5% Potassium disulfite + 5% acetic acid 5 min 
 
Schiff’s reagent recipe: 
1. Dissolve 5 g of basic fuchsin in 900 ml of boiling distilled water. 
2. Cool to approximately 50°C and slowly add 100 ml of 1 N HCl. 
3. Cool to approximately 25°C and dissolve 10 g of K2S2O5. 
4. Shake for 3 minutes and incubate in the dark at room temperature for 24 hours. 
5. Add 5 grams of fine activated charcoal and shake for 3 minutes. 
6. Filter solution (should be clear). 
7. Store at 4°C in a foil covered bottle. 
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3.8.2 Enzymatic deglycosylation with PNGase F 
Peptide: N-Glycosidase F, also known as PNGase F, is an amidase purified from Flavobacterium 
meningosepticum which cleaves between the innermost GlcNAc and asparagines residues of 
high mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins.  
 
Protein-asn-GlcNAc-Glycan  Protein-asp + NH3 + GlcNAc-Glycan 
 
This allows for an indirect detection of N-linked carbohydrates on any given protein. 
 
Typical reaction conditions are as follows: 
1. Combine 1-20 µg of glycoprotein, 1 µl of 10x Glycoprotein Denaturing Buffer and H2O 
(if necessary) to make a 10 µl total reaction volume. 
2. Denature glycoprotein by heating reaction at 100°C for 10 minutes. 
3. Make a total reaction volume of 20 µl by adding 2 µl of 10x G7 Reaction Buffer, 2 µl of 
10% NP-40, H2O and 1-2 µl of PNGase F. 
4. Incubate reaction at 37°C for 3 hours. 
 
After deglycosylation, the protein is run on a SDS polyacrylamide gel, stained with Coomassie, 
and its molecular weight is compared to that of the undigested form. RNAse B is used as a 
control substrate. This protein has an apparent MW of 17 kD containing one glycan chain of high 
mannose type. The apparent MW is reduced to 15 kD upon digestion with PNGase F. 
 
3.9 Isolation of RNA with Quigen RNeasy Mini Kit 
For cell isolation the medium is discarded and the cells are washed with 5 ml of ice cold 1xPBS. 
Then the cells are covered with 1 ml of ice cold 1xPBS. All the following procedures are 
performed on ice. With a cell scraper go once along the edge and then scrape the cells from top 
to bottom. With a Gilson pipette the total volume is transferred to a 1.5 ml Eppendorf tube. Then 
the tubes are centrifuged at 4°C and the supernatant is discarded leaving only the pellet. The 
pellets are stored at -80°C until further use or RNA isolation is started immediately. 
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• Pellet is resuspended in 600 µl RLT buffer and 6 µl of β-mercaptoethanol, the lysate is 
transferred into a QIA shredder column, which is positioned on a 2 ml tube. 
• Centrifuge for 2 min at 13000 to 14000 rpm. 
• Then 600 µl of 70% EtOH are added and then suspend very well. 
• The lysate is transferred onto an RNAeasy column including a 2 ml collection tube. 
• Centrifuge the RNAeasy column for 15 sec at 13000 rpm – this is the critical step where 
binding of the RNA takes place. 
• The flow-through is discarded. 
• First, the column is washed with 700 µl of RW1 and then 2x with RPE buffer, inbetween 
that columns need to be centrifuged for 15 sec, except after the 2nd washing step, here 
centrifugation needs to take place for 2 min. 
• RNAeasy column gets placed on top of a new tube. 
• 30 µl of RNAse free water are pipetted directly on the membrane . 
• centrifuge at 13000 rpm for 1 minute. 
 
Afterwards, a DNAse digestion is performed in order to remove DNA: 
 
30 µl sample 
+ 3.75 µl DNAse (RNase free!) 
+ 3.75 µl buffer   incubate the mix for 30 min at 37°C 
+ 3.75 µl stop solution  this mix is incubated for 10min at 65°C 
 
Centrifuge the whole mix for a few seconds to spin down the condensed water. Measure the 
RNA concentration with a Nanodrop device. RNA can be stored at -80°C, but it is recommended 
to test for remaining genomic DNA by PCR with GAPDH primers prior to reverse transcription 
into cDNA. 
 
3.10 Reverse Transcription of mRNA into cDNA 
For reverse transcription of mRNA into cDNA, oligo-d(T)s are used as primers, since they bind 
to the poly-A tail of mRNA. The enzyme that drives the reaction is an RNA dependent DNA 
polymerase. 
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• 7.5 µg RNA, dissolved in 29.5 µl water, are mixed with 1 µl oligo-d(T) and incubated 
at 70°C for 10 min. 
• then 3 min incubation on ice, after that centrifugation of the tubes at RT for 30 sec 
and 13000 rpm. 
• the next step is to add 1.8 µl of RT-Mix. 
• Incubation of the mix at 42°C for 2 min. 
• Addition of 200 U (=1µl) Superscript Reverse Transcriptase. 
• incubation at 42°C for 50 min. 
• incubation at 70°C for 15 min (the enzyme is deactivated). 
• after deactivation the mix is put on ice for 5 min, followed by centrifugation at RT – 
13000 rpm for 2 min. 
• the cDNA is stored at -20°C.  
 
1x RT-Mix 
 10     µl           5x Reverse Transcriptase buffer 
   5     µl           0.1 M DDT (Dithiothreitol) 
   1.5  µl           RNaseOUT (inhibits RNases, add immediately before use) 
   2     µl           10 mM  dNTPs 
 
3.11 Semi-quantitative RT-PCR 
PCR amplifies the DNA sequences enclosed by two primers, which results in a double stranded 
DNA fragment of a certain length that can be detected on an agarose gel. By reverse 
transcription (RT)-PCR gene expression levels of distinct genes can be analyzed. Therefore 
specific primers are used to amplify cDNA that has been reverse transcribed from mRNA. 
 
Table 3. 6 Contents of one PCR mixture (50µl). 
PCR water (aqua dest.) 38.75 µl 
10x PCR-buffer w/o Mg2+ 5 µl 
25mM MgCl2 3 µl 
10mM dNTPs 1 µl 
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Forward Primer 0.5 µl 
Reverse Primer 0.5 µl 
Taq DNA-Polymerase 0.25 µl 
cDNA 1 µl 
 
For PCR with one primer set for more than 2 samples a master mix (containing everything but 
cDNA) is prepared first, then aliquoted to 49 µl each, cDNA added and one drop of mineral oil 
for PCR with Biometra Trio Thermoblock. For PCR with heated lid apparatus no oil is needed. 
 
Table 3. 7 Standard PCR Program. 
 Temperature Time 
0 94°C 60 sec 
1 94°C 45 sec 
2 Annealing temperature 45 sec 
3 72°C 60 sec 
4 72°C 300 sec 
5 4°C infinitely 
 
Step 1-3 is repeated for 27-40 cycles 
The cycle number for each primer pair was determined so that no saturated signal was obtained. 
 
Annealing temperature 
The annealing temperature is based on the Tm value of the oligonucleotide, at which half of the 
DNA molecules are single stranded. A Tm of -7°C is normally used as annealing temperature, 
since higher temperatures inhibit binding of the primer, and lower temperatures favor unspecific 
binding. The optimal annealing temperature for each primer is usually determined empirically. 
 
The formula for calculating Tm: 2 x (A+T) + 4 x (G+C) = Tm in °C 
 
A more precise formula which also takes into account the salt concentration: 
Tm = 81,5 + 16,6(log10[J+]) + 0,41(%G+C) - (600/l) - 0,63(%FA) 
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[J+]...concentration of monovalent Kations 
l...length of oligonucleotide  
FA...Formamid 
 
Table 3. 8 Annealing temperatures for primers used in this study. 
Primer Annealing Temperature (°C) 
Anf 55 
BCl Xl 64 
GAPDH 55 
Islet-1 60 
Mef-2C 66 
MHCα 60 
Nkx2.5 58 
α -Tropomyosin 55 
 
3.12 Agarose gels for separation of PCR products 
DNA molecules with a length of 0.1 to 60 kb can be separated on agarose gels. The agarose 
percentage of the gel depends on the fragment sizes, for PCR fragments of 200-1200 bp, 1.5-2% 
agarose gels were used. Gels were prepared and run as described in a previous diploma thesis 
(Stary, 2001). As a size marker, a 100 bp DNA ladder (gene ruler, Fermentas) was used. DNA 
on gels was stained with ethidium bromide (15 µl for 150 ml ddH2O) for 20 min and 
photographed under UV-light exposure. 
 
3.13 Karyotyping 
Prepare cells 
1. Harvest the cells by trypsinization and/or pipetting as required and transfer to 15-ml 
tubes. 
2. Centrifuge cell suspension 5 minutes at 1000 rpm, room temperature. 
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3. Remove supernatant, resuspend pellet in remaining supernatant (<0.5 ml) by vortexing 
the tube and adding dropwise 4 ml of pre-warmed (37°C) 75 mM hypotonic KCl buffer. 
4. Incubate 6 minutes at room temperature. 
 
Fix cells 
5. Centrifuge cells 5 minutes at 1000 rpm, room temperature, remove the hypotonic KCl 
solution, and add 4 ml of fresh 3:1 methanol/glacial acetic acid fixative with a Pasteur 
pipet.  
6. Centrifuge the tubes again as in step 5, discard supernatant, and resuspend the cells in 3 
ml fresh 3:1 methanol/glacial acetic acid fixative. Repeat this step once or twice until a 
suitable cell pellet is obtained. 
7. Add 0.5 ml fresh 3:1 methanol/glacial acetic acid fixative and incubate 3 hours at 4°C. 
 
Prepare slides 
8. Clean glass microscope slides with 95% ethanol. Wipe slides with dry lint-free paper 
towels. 
9. Resuspend the cells in a small amount of fresh 3:1 methanol/glacial acetic acid fixative 
until suspension looks slightly turbid (~5x106 cells/ml). Drop 3 to 4 drops evenly on a 
slide covered with a thin film of distilled water. After the slide is completely dry, 
examine with a phase-contrast microscope to check cell density and spread of 
chromosomes. 
If the cell density is too high, add a few more drops of fixative to the cell suspension. If the cell 
density is low, centrifuge the suspension and resuspend the pellet in a smaller amount of fixative. 
10. With a Pasteur pipet, let two drops of cell suspension fall onto each cleaned, wet slide. 
Mark the slide with a diamond pen or pencil. Air dry slide(s) over night in the fume hood. 
11. Stain with Giemsa solution for 2 minutes and rinse with distilled water. 
 
3.14 Alkaline phosphatase assay 
Since embryonic stem cells are known to exhibit increased expression of alkaline phosphatise 
(Resnick et al., 1992), this enzyme can be used as a marker for undifferentiated cells. 
 
1. The cells are washed 2x with 1xPBS for 5 minutes each. 
  55 
2. The cells are pre-incubated with AP buffer for 5 minutes. 
3. AP buffer is sucked off and 1.5 ml of AP coloring solution are added to each well. 
4. Incubation in the dark for 15 minutes. 
5. Stop reaction with distilled water and count blue colonies. 
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4 Results 
The main tasks of my diploma thesis were, first, to successfully express and purify matrix-
associated and diffusible Leukemia Inhibitory Factor (M-LIF and D-LIF, respectively) in their 
glycosylated forms, and second, to test the influence of these cytokines on various types of cells, 
encompassing murine embryonic stem cells (ESCs), primary cardiomyocytes (pCMCs) and 
cardioblast-like stem cells (CBLSCs). Since little is known about the latter cell line, which was 
only recently established and is believed to represent a line of somatic stem cells isolated from 
neonatal mouse hearts, an additional task was to begin thorough characterization of this cell line. 
 
4.1 Characterization of M-LIF and D-LIF 
After expression and purification of M-LIF and D-LIF, Westernblot analysis was conducted to 
confirm identity. For further characterization, the degree of glycosylation was enzymatically 
determined and mass spectrometry analysis was performed.  
 
4.1.1 Expression of M-LIF and D-LIF 
The two LIF isoforms of interest were expressed in Sf9 cells via the baculovirus system. Insect 
cells were chosen, due to their ability to generate posttranslational modifications, such as 
phosphorylation, myristylation, palmitylation, and glycosylation, to name just a few. Since LIF is 
known to be heavily glycosylated (Sasai et al., 1998), these modifications could potentially play 
a key role in activity and/or function of this cytokine. 
Sf9 cells were transiently transfected with baculoviruses containing expression vectors for M-
LIF and D-LIF, respectively. These vectors were constructed and verified by Waltraud Pasteiner 
during the course of her doctoral thesis (Pasteiner, 2006). Both viruses were shown to be equally 
infectious exhibiting a titer of 2.2 x 105 plaque forming units (pfu)/ml, as derived from the viral 
plaque assay conducted in this study. A multiplicity of infection (MOI) of 0.01 pfu/cell was used 
for each infection. Generally, one cycle of infection lasted 96 hours, upon which cells were 
washed, pelleted, and immediately frozen at -80°C. Figure 4.1 shows microphotographs of 
infected and uninfected cells, taken just before harvesting. 
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FIGURE   4.1.      Morphology of Sf9 cells. A, Sf9 cells 4 days after seeding. B, Sf9 cells 4 days after seeding and 
infection with baculoviruses. The cells are visibly bloated and granular, as opposed to the uninfected cells in A. 
Scale bar = 20 µm. 
 
4.1.2 Purification of M-LIF and D-LIF 
Since the expression vectors for M-LIF and D-LIF, respectively, contain a carboxy-terminal 
stretch coding for six consecutive histidines, immobilized-metal affinity chromatography 
(IMAC) using the chelating ligand nitrilotriacetic acid (NTA) charged with Ni2+ and coupled to 
agarose beads was chosen for purification. NTA occupies four of the six ligand binding sites in 
the coordination sphere of the nickel ion, leaving two sites free to interact with the 6xHIS tag 
(Figure 4.2). LIF was purified from cell pellets using the batch system and competitively eluted 
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FIGURE   4.2.      Interaction between neighboring residues in the 6xHIS tag and Ni-NTA matrix (The 
QIAexpressionist, 2003). 
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with two different concentrations of imidazole. Four elution fractions were collected, the first 
two of which were obtained with 50 mM of imidazole, the second two with 250 mM of 
imidazole. Since elution steps 3 and 4 were carried out under more stringent conditions than 
elution steps 1 and 2, the ratio of LIF to background protein was considered to be more 
favourable in elution fractions 3 and 4. Therefore, these fractions were used for subsequent 
activity assays after pooling and dialysis. Figure 4.3 shows a typical elution profile of M-LIF 
which was in no case visibly distinguishable from that of D-LIF. 
 
FIGURE   4.3.      Purification of M-LIF by Ni++-affinity chromatography. Elution fractions 1-4 (E1-4) and the 
initial protein extract (EX) of Sf9 cells infected with baculoviruses containing the expression vector for M-LIF are 
shown on a Coomassie stained SDS polyacrylamide gel. An unglycosylated, truncated form of M-LIF is visible at a 
MW of approximately 19 kD. Glycosylated forms are less visible, but have been clearly detected at a MW ranging 
from 30-40 kD in subsequent Western blot analysis (see Figure 4.5). The band seen at approximately 37 kD does not 
represent a form of LIF, since it was also observed in control extracts (see Figure 4.4). 
 
Samples to be used for activity analyses were freed from salts and imidazole via dialysis across a 
semi-permeable membrane, and protein concentration was calculated. Photometric analysis was 
used to determine total protein content, of which 2% were estimated to be LIF. This estimation is 
based on mass spectrometry analyses of previous purifications conducted in our laboratory.  
From Coomassie stained SDS polyacrylamide gels we concluded that LIF was expressed only at 
low levels. For this reason, samples of M-LIF, D-LIF, and a control fraction were run on a SDS 
polyacrylamide gel which was silver stained in order to enhance signal sensitivity (Figure 4.4). 
On such gels, purified LIF could be identified very clearly. As expected, glycosylated forms 
ttttttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tttttt ttttttt tttttt tttttt 
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FIGURE   4.4.      Silver stain analysis of purified M-LIF and D-LIF. Elution fraction 1 of Sf9 cells infected with 
baculoviruses containing the expression vector for M-LIF (M-LIF E1), Sf9 cells infected with baculoviruses 
containing the expression vector for D-LIF (D-LIF E1), and uninfected Sf9 cells (CT E1) are shown on a silver 
stained SDS polyacrylamide gel. A truncated form of LIF at a MW of 19 kD can clearly be seen in D-LIF E1 and 
M-LIF E1, as well as glycosylated forms between 30 and 40 kD.  These bands do not appear in CT E1. 
 
ranging from a molecular weight (MW) of 30 to 40 kD can be seen, but interestingly also what 
appears to be an unglycosylated form at 19 kD. Since full-length, unglycosylated LIF containing 
a HIS-tag must in theory be heavier than 20 kD, this form can only be a truncated version of LIF. 
 
4.1.3 Western blot analysis of M-LIF and D-LIF 
To confirm the presence of LIF in the purified samples, Western blots were performed with 
αLIF antibodies and α6xHIS antibodies, respectively. Samples of several different purification 
runs were analyzed, revealing that LIF expression and purification had been successful in every 
case, but apparently highly variable from bout to bout, judging from differences in band 
intensities on Western blots. Samples that were obtained from one particularly favorable passage 
of expression and purification are shown in Figure 4.5, after Western blot analysis with αLIF 
and α6xHIS antibodies, respectively. As already observed after silver staining, several bands can 
be seen at a MW between 30 and 40 kD and one distinct band at 19 kD.  
Additionally, Western blot analyses were conducted with samples taken from culture medium 
that had been kept after infection. Fairly high amounts of LIF could be detected with αLIF 
ttttttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tt 
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FIGURE   4.5.      Identification of  M-LIF and D-LIF isoforms by Western blot analysis. A, Western Blot of 
elution fraction 1 (E1) of purified M-Lif and D-Lif, respectively, with α LIF antibodies. Glycosylated forms are 
visible in the range of 30-40 kD as well as a truncated, unglycosylated form at approximately 19 kD. B, WesternBlot 
with α 6x HIS antibodies. Again, glycosylated and truncated forms of LIF can be seen. Bands >40 kD are 
unspecific, since they were also detected in the control fraction (not shown). 
 
antibodies in the unconcentrated and unpurified sample, with D-LIF showing consistently higher 
levels than M-LIF (Figure 4.6). A densiometric analysis was performed, revealing a significantly  
 
FIGURE   4.6.      Sf9 cells produce similar amounts of M-LIF and D-LIF, but secrete much more D-LIF. A, 
Elution fraction 1 (E1) of M-LIF and D-LIF purified from Sf9 cells. Levels for intracellular M-LIF and D-LIF are 
comparable.  B+C, Analysis of M-LIF and D-LIF levels, respectively, in the culture medium of infected Sf9 cells 
taken from two separate rounds of infection. In both cases, more D-LIF than M-LIF could be detected, suggesting a 
difference in secretion of the two isoforms. 
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higher amount of D-LIF in all analyzed samples (Figure 4.7). Since M-LIF and D-LIF were 
proven to be obtainable in equal amounts when isolated from cell lysates (Figure 4.6, A), we may 
conclude that M-LIF and D-LIF are secreted to a different degree, with D-LIF being the more 
favorably secreted isoform. 
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FIGURE   4.7.      SF9 cells secrete 3-times more LIF than M-LIF. Expression of d-lif and m-lif cDNA under the 
control of the same promoter resulted in an equal amount of M-LIF and D-LIF protein in the SF9 cell lysates 
(cytoplasm) but D-LIF secretion into the medium (extracellular) was significantly increased. Protein concentration 
was determined in cell lysates from equal numbers of SF9 cells and from equal volumes of culture medium, 
respectively, by Western blot analysis with α LIF antibodies and densiometric analysis of NBT/BCIP stained 
nitrocellulose membranes with the program photoshop CS2. Error bars indicate standard deviation σx(n−1); N=3 
 
Moreover, these data reveal that both isoforms of LIF were highly present in infected culture 
medium. If biological function is proven to be identical to that of intracellularly derived LIF, 
using culture medium to obtain and purify LIF would be advisable for future experiments, due to 
the far greater yields thereby achievable. 
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4.1.4 Determination of glycosylation 
The next step was to confirm glycosylation of both LIF isoforms. A Western blot was performed 
in which M-LIF and D-LIF were compared to commercial LIF that had been produced in E.coli 
and therefore had to be naturally devoid of glycosyl moieties.  
 
FIGURE   4.8.      LIF produced in this study is posttranslationally modified, as opposed to purchased LIF. 
Western Blot of purchased LIF (Chemicon) and elution fraction 1 (E1) of purified M-Lif and D-Lif, respectively, 
with α LIF antibodies. Bands in the range of 30-40 do not appear in the lane containing purchased LIF. 
 
In Figure 4.8, we see that commercial LIF lacks the bands ranging from 30 - 40 kD which are 
present in M-LIF and D-LIF. This finding confirms the presence of posttranslational 
modifications in M-LIF and D-LIF and a lack thereof in purchased LIF. 
To investigate if these modifications were glycosidic in nature, enzymatic deglycosylation of the 
purified samples and subsequent Western blot analysis with αLIF antibodies were performed. As 
can be seen in Figure 4.9, the bands at 30 - 40 kD were successfully reduced to a single band at 
approximately 23 kD upon treatment with the deglycosidase PNGase F. This confirms the 
existence of several glycosylated subtypes of LIF in the purified samples. Since the MW of one 
complex N-linked glycosyl moiety was calculated to be 2.86 kD and deglycosylated LIF has a 
MW of 23 kD, the presence of six glycosyl moieties on M-LIF and D-LIF, respectively, can be 
assumed, correlating with previously published data (Sasai et al., 1998). 
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FIGURE   4.9.      Glycosidase treatment of M-LIF and D-LIF. Elution fraction 1 (E1) of purified M-LIF and D-
LIf, respectively, were treated with PNGase F and analyzed by Western blotting. The glycosylated forms of LIF (30-
40 kD) were successfully reduced to a single band at a MW of approximately 23 kD. 
 
4.1.5 Sequencing of M-LIF and D-LIF 
The final step in the characterization process was to analyze the sequences of the amino-termini 
of both purified isoforms of LIF. Since M-LIF and D-LIF differ from one another by only three 
amino acids in length (corresponding to a MW of 0.38 kD) a difference in molecular weight 
between the two isoforms cannot be determined by visualization on a SDS polyacrylamide gel. 
Furthermore, it stands to question if the complete amino-termini are even present in the mature 
forms of M-LIF and D-LIF, since it has been previously reported that the complete leader 
sequences upstream of amino acid 24 could not be detected by sequence analysis (Rathjen et al., 
1990). Therefore, samples of M-LIF and D-LIF were submitted several times to the VBC mass 
spectrometry unit for thorough analysis of the protein sequences. 
The first samples submitted were the truncated forms of M-LIF and D-LIF at a MW of 
approximately 19 kD. As can be derived from Figure 4.9, the samples were doubtlessly 
identified as LIF. However, no peptides upstream of amino acid H39 in the case of D-LIF or H36 
in the case of M-LIF (hereinafter referred to as H39/36), and downstream of K193 or K190, 
respectively (hereinafter referred to as K193/190), could be detected. Since the presence of 
carboxy-terminal 6xHIS tags had already been confirmed by Western Blot analysis (Figure 4.5 
B), it is obvious that amino acids downstream of K193/190 must be present. This, in effect, 
leaves only the possibility of this particular form of LIF being truncated at the amino-terminus,  
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D-LIF 
              
  
        
     1 MKVLAAGIVP LLLLVLHWKH GAGSPLPITP VNATCAIRHP CHGNLMNQIK  
    51 NQLAQLNGSA NALFISYYTA QGEPFPNNVE KLCAPNMTDF PSFHGNGTEK  
   101 TKLVELYRMV AYLSASLTNI TRDQKVLNPT AVSLQVKLNA TIDVMRGLLS  
   151 NVLCRLCNKY RVGHVDVPPV PDHSDKEAFQ RKKLGCQLLG TYKQVISVVV  
   201 QAF 
       
          
M-LIF 
        
          
     1 MRCRIVPLLL LVLHWKHGAG SPLPITPVNA TCAIRHPCHG NLMNQIKNQL  
    51 AQLNGSANAL FISYYTAQGE PFPNNVEKLC APNMTDFPSF HGNGTEKTKL  
   101 VELYRMVAYL SASLTNITRD QKVLNPTAVS LQVKLNATID VMRGLLSNVL  
   151 CRLCNKYRVG HVDVPPVPDH SDKEAFQRKK LGCQLLGTYK QVISVVVQAF  
                
 
FIGURE   4.9.      Identification of truncated M-LIF/ D-LIF by mass spectrometry analysis after digestion 
with Trypsin. The submitted proteins were successfully identified as LIF (detected amino acids are shown in red). 
Amino acids upstream of H39/36 were not found. 
 
which is in accordance with the finding that the missing amino acids amount to a molecular 
weight of approximately 4 kD. 
After this analysis, samples of deglycosylated LIF with a MW of approximately 23 kD were 
submitted for examination. First, LysC was used in the fragmentation process, as opposed to 
Trypsin, which had been used in the former analysis. LysC was chosen, as it would theoretically 
generate larger, hence, more easily detectable fragments than Trypsin, due to the fact that LysC 
recognizes fewer cleavage sites within the first 40 amino acids. Again, the samples were 
undeniably identified as LIF, although fewer peptides could be determined this time around 
(Figure 4.10). It was possible, though, to identify three amino acids directly upstream of H39/36 
in the case of D-LIF, and 6 amino acids directly upstream of H39/36 in the case of M-LIF. Thus, 
it was proven that amino-acids upstream of H39/36 were present in this form.  
Finally, a third mass spectrometry analysis was performed. This time, the deglycosylated 23 kD 
form was digested with Subtilisin prior to analysis. Subtilisin is a serine endopeptidase which 
hydrolyses proteins with broad specificity for peptide bonds. Figure 4.11 shows that the carboxy-
terminus was almost completely identified in this analysis. As for the amino-terminus, the first 
amino acid detected this time was S24 for D-LIF and S21 for M-LIF, respectively (hereinafter 
referred to as S24/21).  
At face value, the results obtained from these analyses suggest that the truncated form of LIF 
present in our samples begins with amino acid H39/36 and “full-length” LIF with amino acid 
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D-LIF 
              
  
        
     1 MKVLAAGIVP LLLLVLHWKH GAGSPLPITP VNATCAIRHP CHGNLMNQIK  
    51 NQLAQLNGSA NALFISYYTA QGEPFPNNVE KLCAPNMTDF PSFHGNGTEK  
   101 TKLVELYRMV AYLSASLTNI TRDQKVLNPT AVSLQVKLNA TIDVMRGLLS  
   151 NVLCRLCNKY RVGHVDVPPV PDHSDKEAFQ RKKLGCQLLG TYKQVISVVV  
   201 QAF 
       
          
M-LIF 
        
          
     1 MRCRIVPLLL LVLHWKHGAG SPLPITPVNA TCAIRHPCHG NLMNQIKNQL  
    51 AQLNGSANAL FISYYTAQGE PFPNNVEKLC APNMTDFPSF HGNGTEKTKL  
   101 VELYRMVAYL SASLTNITRD QKVLNPTAVS LQVKLNATID VMRGLLSNVL  
   151 CRLCNKYRVG HVDVPPVPDH SDKEAFQRKK LGCQLLGTYK QVISVVVQAF  
                
 
FIGURE   4.10.      Identification of M-LIF/ D-LIF by mass spectrometry analysis after digestion with LysC. 
The submitted proteins were successfully identified as LIF (detected amino acids are shown in red). Three amino 
acids upstream of H39/36 were found in the case of D-LIF, six in the case of M-LIF. 
 
D-LIF 
              
          
     1 MKVLAAGIVP LLLLVLHWKH GAGSPLPITP VNATCAIRHP CHGNLMNQIK  
    51 NQLAQLNGSA NALFISYYTA QGEPFPNNVE KLCAPNMTDF PSFHGNGTEK  
   101 TKLVELYRMV AYLSASLTNI TRDQKVLNPT AVSLQVKLNA TIDVMRGLLS  
   151 NVLCRLCNKY RVGHVDVPPV PDHSDKEAFQ RKKLGCQLLG TYKQVISVVV  
   201 QAF 
       
          
M-LIF 
        
          
     1 MRCRIVPLLL LVLHWKHGAG SPLPITPVNA TCAIRHPCHG NLMNQIKNQL  
    51 AQLNGSANAL FISYYTAQGE PFPNNVEKLC APNMTDFPSF HGNGTEKTKL  
   101 VELYRMVAYL SASLTNITRD QKVLNPTAVS LQVKLNATID VMRGLLSNVL  
   151 CRLCNKYRVG HVDVPPVPDH SDKEAFQRKK LGCQLLGTYK QVISVVVQAF  
                
 
FIGURE   4.11.      Identification of M-LIF/ D-LIF by mass spectrometry analysis after digestion with 
Subtilisin. The submitted proteins were successfully identified as LIF (detected amino acids are shown in red). The 
first amino acid detected was S24 or S21, respectively. 
 
S24/21, meaning that preceding peptides must in some way have been cleaved off. In an attempt 
to verify this hypothesis, the apparent amino-termini were bioinformatically analyzed for 
enzyme restriction sites using the Expert Protein Analysis System (http://expasy.org). Results 
show that there is indeed a cleavage site for several enzymes directly upstream of H39/36, 
however, no enzymes could be shown to cleave directly upstream of S24/21 (Figure 4.12). 
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FIGURE   4.12.      Restriction sites upstream and downstream of H39/36 and S24/21. Amino acid sequences of 
LIF in the region of H39/36 and S24/21, respectively, were analyzed with EXPASY’s “peptide cutter” program for 
restriction sites with all available enzymes. A, Three enzymes were found to cut directly upstream of H39/36. B, No 
enzyme was found to cleave directly upstream of S24/21. 
 
4.2 The influence of M-LIF and D-LIF on embryonic stem 
cells 
Leukemia Inhibitory Factor is best known for its positive effect on the self-renewal capacity of 
embryonic stem cells (ESCs) (Smith et al., 1988; Williams et al., 1988). Therefore, ESCs were 
the first cells chosen in this study to analyze biological function and activity of recombinant M-
LIF and D-LIF. 
 
4.2.1 Influence on self-renewal capacity 
A typical property of LIF is the maintenance of self-renewal, i.e. the ability to keep stem cells in 
a proliferating, undifferentiated state. In the absence of LIF or LIF-producing feeder cells, ESCs 
begin to spontaneously differentiate in vitro after several days. Therefore, the first point of 
interest was to test purified recombinant M-LIF and D-LIF in terms of their functionality 
concerning ESC-self-renewal. This was done by conducting an Alkaline Phosphatase assay (AP 
assay), in which M-LIF and D-LIF, respectively, were added at various concentrations to ESCs 
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for 4 days. Recombinant, unglycosylated LIF (Chemicon International), which had been 
produced in E.coli, was used as a control, as well as extract of uninfected Sf9 cells. As a third 
control, cells were left untreated. Commercial LIF was added at concentrations ranging from 0.5 
to 5 ng/ml. Since the calculated concentrations for M-LIF and D-LIF relied on estimation (see 
4.1.2) and were therefore potentially imprecise, these proteins were added at considerably higher 
concentrations and a broader range of 10 to 100 ng/ml. 
ESCs were plated in 6-well plates at a very low density (5000 ESC per well) in order to avoid 
support by cell-cell contact. On day 5, cell colonies were analyzed for Alkaline Phosphatase 
activity, after which coloration and morphology were observed. A classification of degree of 
differentiation was established, ranging from undifferentiated to differentiated (Figure 4.13).  
 
                       
 
FIGURE   4.13.      Colonies of embryonic stem cells (ESCs) evaluated in AP Assay.  A, Undifferentiated. B, 
Slightly differentiated. C, Nearly all differentiated. D, Differentiated. Scale bar = 20µm. 
 
Alkaline Phosphatase is known to be expressed in undifferentiated ESCs at a high level and is 
therefore often used as a stem cell marker (Resnick et al., 1992). Thus, undifferentiated colonies 
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appear dark blue after reaction with NBT/BCIP and are morphologically dense, small and round 
in shape (Figure 4.13 A). Cells in differentiated states show increasingly less coloration and 
density, with a higher number of protrusions (Figure 4.13 B,C,D).  
After evaluation of each well, results of untreated cells and cells treated with LIF stood in stark 
contrast to one another (Figure 4.14). Almost half of all colonies counted in wells containing  
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FIGURE   4.14.      Analysis of the self renewal capacity of embryonic stem cells (ESCs) in the presence of 
LIF. A, Nearly half of all colonies counted in wells containing untreated cells appeared to be fully differentiated 
with only 10% showing complete undifferentiation. Error bars indicate standard deviation σx(n−1); N=2 B, Cells 
treated with the Sf9 extract (SF9 CT) showed a slightly higher degree of undifferentiation as compared to untreated 
cells, which was dependant on the concentration. C+D+E, More than half of the colonies counted in wells 
containing cells treated with purified M-LIF, purified D-LIF and commercial LIF (Chemicon), respectively, showed 
complete undifferentiation at their highest concentration. Furthermore, no fully undifferentiated colonies were 
present in these wells.  
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untreated cells appeared to be fully differentiated with only 10% showing complete 
undifferentiation (Figure 4.14 A). Colonies treated with LIF, however, showed no signs of 
terminal differentiation and more than half of the analyzed colonies remained completely 
undifferentiated at the highest concentration (Figure 4.14 C,D,E). Interestingly, purified extract 
of uninfected Sf9 cells also had a slightly renewing effect when added to the culture medium of 
ESCs. However, the effect was far weaker than that of LIF, reaching a total percentage of 
undifferentiation of only 20% at its highest concentration, with an equal amount of terminally 
differentiated colonies visible (Figure 4.14 B). 
Since 100 ng/ml of M-LIF and D-LIF, respectively, displayed an equivalent degree of biological 
activity to 10 ng/ml of commercial LIF, these concentrations were used in all subsequent 
experiments. 
 
4.2.2 Influence on embryoid body development 
To test the effect of M-LIF and D-LIF, respectively, on cardiomyogenesis in embryoid bodies 
(EBs), the two cytokines were added at two distinct time points during early EB development – 
day 5 and day 7, respectively. Controls were EBs treated with unglycosylated LIF (Chemicon 
International) or extract of uninfected Sf9 cells, respectively, and untreated EBs. EBs were 
observed from day 7 to 11 and the percentage of EBs containing beating cells was determined. 
As can be seen in Figure 4.15, M-LIF and D-LIF inhibited cardiomyocyte development to a 
slight degree when added on day 5, and to a more significant when added on day 7. In both 
cases, the inhibiting effect of M-LIF was marginally greater than that of D-LIF. Surprisingly, 
unglycosylated LIF did not exhibit this effect, having little or no effect when added on day 5 and 
even a slightly positive effect, as compared to untreated EBs, when added on day 7. The Sf9 cell 
extract showed no noteworthy effect when added on day 5, but a slight retarding effect when 
added on day 7, which however lasted only until day 9. 
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FIGURE   4.15.      Embryoid body (EB) development in the presence of LIF. Embryoid bodies were generated 
and treated with 10 ng/µl of LIF (Chemicon), 100 ng/µl of M-LIF, 100 ng/µl of  D-LIF, 100 ng/µl of Sf9 extract 
(SF9 CT) or left untreated (CT), respectively. EBs with beating cardiomyocytes were counted from day 7-11. A, M-
LIF and D-LIF slightly retard EB development when administered on day 5. B, M-LIF and D-LIF drastically retard 
EB development when administered on day 7. C, Mean values calculated from data sampled from day 8/9 of A. D, 
Mean values calculated from data sampled from day 9/10 of B.  Error bars indicate standard deviation σx(n−1); N=2 
 
4.3 The influence of M-LIF and D-LIF on primary 
cardiomyocytes 
Increased proliferation and longevity of primary cardiomyocytes (pCMCs) has previously been 
demonstrated when grown on parietal endoderm (PE) overexpressing M-LIF (Pasteiner, 2006). 
This beneficial effect could not be observed when grown on PE overexpressing D-LIF. To 
answer the question of whether this phenomenon could be reproduced by administering LIF in 
recombinant form, experiments were performed, in which primary cardiomyocytes were treated 
with recombinant M-LIF and D-LIF, respectively, that had been expressed and purified in this 
study. 
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4.3.1 Influence on morphology and contractility/proliferation 
Primary cardiomyocytes were isolated from d1-2 neonatal wild-type mice and cultivated on 
gelatinated 10-cm plates. After attachment of cells (one day after seeding), they were treated 
daily with M-LIF and D-LIF, respectively. Controls were treated with purchased LIF, Sf9 extract 
or no agent, respectively. Areas containing beating cells were marked and observed over the 
course of 7-10 days. Morphology was inspected, as well as contractile ability and proliferation, 
by counting the number of beating cells within a marked area.  
In the first of these experiments, the agents were added to the cells at an interval of 48 hours 
(Figure 4.16, A). This may explain the periodically fluctuating amount of beating cells 
ttttttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tttttt tttttt ttttttt tttttt ttttttt tttttt 
 
FIGURE   4.16.      The influence of LIF on contractile ability / proliferation of primary cardiomyocytes 
(pCMCs). Primary cardiomyocytes were isolated and LIF was added every second day (A) or every day (B,C), 
respectively, at a concentration of 100 ng/µl (M-LIF, D-LIF) or 10 ng/µl (LIF(Chemicon)), respectively. Areas 
containing beating cells were analyzed for contractile activity. A, A fluctuating activity profile can be seen for M-
LIF and D-LIF treated cells which can be ascribed to the time-points at which LIF was added to the medium. M-LIF 
and D-LIF seem to slightly promote longevity of beating cells. B, To a very similar degree, M-LIF and D-LIF 
apparently promote contractile activity when added on a daily basis. C, Beginning with day 5, M-LIF and D-LIF 
seem to promote activity. D, Mean values calculated from data sampled from day 4-7 of B.  Error bars indicate 
standard deviation σx(n−1); N=4 
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encountered. Between day 1 and 5 neither M-LIF, nor D-LIF, displayed any significant effect on 
the number of beating cells, when compared to untreated cells. On day 6, however, a stark 
contrast between M-LIF and D-LIF treated cells, respectively, and control cells became visible, 
the highest number of beating cells being registered in wells treated with M-LIF. By day 8, 
beating cells had dropped to 25% of the initial number in untreated wells, whereas approximately 
50% of cells initially showing contractility were still beating in M-LIF and D-LIF treated wells, 
respectively. It is interesting to note, that purchased LIF did not display any increase in the 
number of contracting cells, even displaying a consistently lower number than untreated wells 
throughout the first 5 days.  
In the second experiment (Figure 4.16, B), the agents were added to the wells every day 
following attachment, in hopes to avoid obtaining fluctuating activity profiles, such as in the first 
experiment. This time, more even graphs were obtained, with curves for M-LIF and D-LIF 
treated wells rising steadily from day 2-7. On the final day of observation, the number of beating 
cells in M-LIF treated wells had risen to nearly 300%, representing an increase by roughly 
200%, as opposed to an increase by only 10% in untreated wells. D-LIF had a similar effect, 
achieving an increase of almost 160%. Both unglycosylated LIF and Sf9 extract showed a minor 
beneficial effect on contractility/proliferation, achieving an increase by approximately 60% on 
day 7. 
In the third experiment of this nature (Figure 4.16, C), M-LIF and D-LIF again showed a 
promoting effect beginning on day 5. On day 6, more than twice the amount of beating cells was 
counted in wells treated with M-LIF, compared to wells containing untreated cells. A substantial 
increase in terms of longevity could however not be shown, since nearly all cells had stopped 
beating in each of the wells by day 10.   
In regard to morphology, a certain degree of hypertrophy could be detected for cells in all wells 
(Figure 4.17). The addition of LIF did not appear to promote hypertrophy by a significant degree 
in these experiments. 
 
4.3.2 Influence on gene expression 
To investigate the effect of M-LIF and D-LIF, respectively, on the expression of cardiospecific 
genes in pCMCs, semi-quantitative RT-PCR was performed (Figure 4.18). pCMCs were treated 
with LIF and controls as previously described, and mRNA was isolated on days 6 and 10, 
respectively. mRNA was reverse transcribed to cDNA and used as a template for PCR reactions  
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FIGURE   4.17.      Isolated primary cardiomyocytes (pCMCs). A, A colony of pCMCs one day after isolation. 
B, The same colony of pCMCs 6 days after isolation. A certain degree of hypertrophy is apparent. Scale bar = 50 
µm. 
 
with various pairs of primers for a number of different cardiac marker genes (ANF, MHC α, 
BCL-XL, NKX 2.5, MEF 2C, Tropomyosin α). The well-known housekeeping gene GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) was used as a loading control. 
 
FIGURE   4.18.      Analysis of the expression of various cardiac marker genes in the presence of LIF by RT-
PCR.  mRNA of pCMCs, which had been treated daily with 10 ng/µl of LIF (Chemicon, Ch), 100 ng/µl of M-LIF 
(M), 100 ng/µl of D-LIF (D), 100 ng/µl of Sf9 extract (SF9) or left untreated (CT), respectively, was isolated on day 
6 and day 10 after plating, respectively, transcribed to cDNA and analyzed for the presence of various cardiac 
markers. On day 10, M-LIF treated pCMCs expressed consistently higher levels of mRNA for all tested marker 
genes than D-LIF treated cells (red boxes). cDNA was normalized by leveling the GAPDH PCR product. 
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On day 6, ANF expression was upregulated in cells treated with M-LIF, D-LIF and commercial 
LIF, respectively. MHC α expression was similar for all cells, with slight upregulation in cells 
treated with purchased LIF. In the case of the antiapoptotic gene BCL-XL, a striking difference 
could be observed between M-LIF and D-LIF treated cells, with upregulation apparently caused 
by M-LIF and downregulation by D-LIF. This scenario seems to be reversed in terms of NKX 
2.5 and MEF 2C expression, with higher levels of mRNA in the presence of D-LIF. The late 
cardiospecific marker Tropomyosin  α is apparently down-regulated in all treated cells.  
On day 10, a striking difference between M-LIF and D-LIF treated cells could be observed for 
the expression of all analyzed marker genes, with notable downregulation in the presence of D-
LIF. mRNA levels in the presence of M-LIF were consistently higher, but only exceeded control 
levels in the case of BCL-XL and Tropomyosin α, respectively. Treatment with purchased LIF 
showed apparent downregulation regarding expression of MHC α, BCL-XL and NKX 2.5. 
 
4.4 The influence of M-LIF and D-LIF on cardioblast-like 
stem cells 
4.4.1 Influence on proliferation 
To ascertain, whether M-LIF and D-LIF have the same effect on  cardioblast-like stem cells 
(CBLSCs) as on ESCs regarding proliferation, CBLSCs were plated onto gelatinated 24-wells 
plates at a density corresponding to 1/10 of confluence (~3x105 cells/well)  and treated with M-
LIF, D-LIF, and Sf9 control extract, respectively, or left untreated. On day 5, cells were 
trypsinized and cell numbers were measured (Figure 4.19). As expected, treatment with either 
form of LIF led to a drastic increase in cell number, showing a 10-fold increase in the presence 
of M-LIF and an 11-fold increase in the presence of D-LIF, respectively, when compared to the 
initial values. This is approximately twice as much as the increase found in untreated cells (~5-
fold). As already identified for ESCs in the AP-assay (see 4.2.1), the Sf9 control extract also 
demonstrated a certain degree of biological activity, generating an 8-fold increase in cell number 
within 5 days.  
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FIGURE   4.19.      Proliferation of cardioblast-like stem cells (CBLSCs) in the presence of LIF. 3x 105 cells 
were seeded per well and treated with 100 ng/µl of M-LIF, 100 ng/µl of D-LIF, 100 ng/µl of SF9 extract (SF9 CT) 
or left untreated (CT), respectively, for 4 days. On day 5 they were counted with a Coulter Counter. Treatment with 
either LIF isoform led to the generation of approximately twice as many cells compared to untreated cells (CT), with 
D-LIF showing a slightly higher effect than M-LIF. Error bars indicate standard deviation σx(n−1); N=2 
 
4.4.2 Influence on differentiation 
Following this experiment, an in vitro differentiation assay was conducted. CBLSCs from the 
former experiment that had been treated for four days with M-LIF, D-LIF, and Sf9 control 
extract, respectively, or left untreated were seeded onto gelatinated 6-well plates at densities of 
1:50, 1:100 and 1:500, respectively, and incubated at 37°C. 12 days after plating, cells were 
observed in a microscope. 
Surprisingly, a marked difference in development had taken place between treated and untreated 
cells (Figure 4.20). First, treated cells had apparently expanded at a higher rate than control cells, 
since wells containing treated cells at a dilution of 1:500 showed higher density and 
discoloration of growth medium, implying higher nutritious demands most likely caused by the 
increased cell number. At a dilution of 1:100, confluence had been reached in wells containing 
cells treated with M-LIF, D-LIF, and Sf9 control extract, respectively, as opposed to wells 
containing untreated cells. Morphologically, cells in the control wells seemed to be for the most 
part undifferentiated or semi-differentiated, judging from their small size and round shape. 
Furthermore, cells seemed to be growing on top of one another. This stood in strong contrast to 
the morphology of LIF treated cells, which were bigger, flatter and often triangular in shape, 
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FIGURE   4.20.      In vitro differentiation of Cardioblast-like stem cells (CBLSCs). A, CBLSCs initially treated 
with M-LIF. On day 12 after replating, a monolayer of what appeared to be cardiomyocytes was observed with a 
large number of beating aggregates. One such aggregate is circled in red. B, CBLSC initially treated with D-LIF. As 
was the case for cells initially treated with M-LIF, a monolayer of apparent cardiomyocytes exhibiting contractile 
ability was observed. C, CBLSCs initially treated with Sf9 extract. Most cells in this well seemed to be 
undifferentiated. A few beating areas were detected, which contracted at a significantly higher frequency than the 
cells in A and B. D, Untreated cells. In this case, almost all cells appeared to remain undifferentiated, none of which 
exhibited contractile ability. Scale bar = 50 µm. 
 
quite similar to pCMCs. Since some of these cells were also beating rhythmically, there remains  
no doubt that heart cells had accrued, induced either directly or indirectly by the addition of M-
LIF and D-LIF, respectively. This fact became even clearer upon observation of cells that had 
been plated at a dilution of 1:50. In wells containing cells treated with either M-LIF or D-LIF, a 
huge number of beating cells could be detected, the number far exceeding that counted in the 
1:100 dilution. These beating cells appeared in clusters (Figure 4.20 A) and contracted at a 
frequency of approximately 50 beats per minute (bpm). Beating cells were also observed in wells 
that had been treated with the Sf9 control extract. However, two important differences to the 
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former case must be taken into account: First, these cells had not formed a monolayer and were 
small, round and tightly packed (Figure 4.20 C). Furthermore, beating areas of cells contracted at 
a considerably quicker pace, averaging approximately 80 bpm. 
Control cells that had never been treated with any of the aforementioned substances displayed 
absolutely no contractile ability. Small and round in shape, the majority of these cells seemed to 
have remained undifferentiated (Figure 4.20 D). It must be noted that such cells were also found 
in wells of cells treated with LIF. However, they seemed to be for the most part dead, as they 
were not attached to the plate or cell monolayer. 
 
4.5 Characterization of cardioblast-like stem cells 
Since little is known regarding the exact nature of cardioblast-like stem cells, it would be of great 
interest to meticulously characterize these cells in order to decipher their inherent capabilities 
and make out which and how many of these characteristics differ from those typical for 
embryonic stem cells. This characterisation process was started in the later stages of this study. 
 
4.5.1 Growth rate of cardioblast-like stem cells 
The first step undertaken in terms of characterization was the establishment of a growth curve 
and calculation of the doubling time (DT) (Figure 4.21). An initial cell number of 5x104 cells 
was seeded per well, and cell numbers were counted every 48 hours. In order to determine the 
doubling time of CBLSCs, time-points 3 and 4 which lie within the linear portion of the graph 
(representing the exponential phase of the growth curve) were used. According to this 
calculation, a DT of 29.9 hours was determined. Doubling times for ESCs have been reported to 
lie within the range of 22 and 24 hours, thus, the growth rate of CBLSCs seems to be slower than 
that of ESCs. 
 
4.5.2 Karyotyping of cardioblast-like stem cells 
To exclude the possibility of CBLSCs constituting cells generated by fusion of heart cells and 
ESCs, karyotyping was performed (Figure 4.22). In the case of a possible fusion event, polyploid 
chromosome spreads would have to be detectable in CBLSCs. After analysis, all cells were 
found to be diploid in nature, as none of the analyzed chromosome spreads (N=73) displayed 
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FIGURE   4.21.      Growth curve for cardioblast-like stem cells (CBLSCs).  50 000 cells were seeded on 6 wells 
each of a 24-well plate containing feeder layers. One well was sacrificed every 48 hours and cells were counted with 
a Coulter counter. 
 
more than the 40 chromosomes naturally occurring in mouse cells. This affirms the notion of 
CBLSCs as an autonomous, somatic stem cell line. 
 
FIGURE   4.22.      Karyotyping for cardioblast-like stem cells (CBLSCs). Polyploidy was never encountered, 
ruling out the possibility of CBLSCs being a hybrid cell line, possibly generated by fusion of cardiac stem cells and 
embryonic stem cells, the latter of which were used as bystander cells during the isolation process. Scale bar = 50 
µm. 
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4.5.3 Single-cell cloning of cardioblast-like stem cells 
Due to the fact that CBLSCs had been isolated in co-culture with ESCs as described in a 
previous study (Weber, 2006), the possibility of CBLSCs constituting a mixed culture of somatic 
and embryonic stem cells exists. Therefore, cells were subcloned and selected for with G418. 
Since CBLSCs had been isolated from the heart tissue of HDAC1 +/- mice possessing a 
neomycin-resistance-gene, any ESCs should be eliminated by administering the neomycine 
analogue G418. 
In order to achieve this, approximately 200 cells were seeded onto a 6-cm plate containing a 
feeder cell layer and treated daily with 180 µg/ml of G418, beginning 48 hours after attachment. 
One week after seeding, microphotographs were taken (Figure 4.23 A). When compared to a 
colony of ESCs (Figure 4.23 B) several morphologic differences become evident: CBLSCs 
appear larger than ESCs. Colonies of CBLSCs are more rounded-up and lack the sharp 
circumference displayed by colonies of ESCs. Moreover, CBLSCs seem to be less attached to 
feeder cells and to each another, also exhibiting less overgrowth as opposed to ESCs. These 
striking morphologic differences strongly suggest an independent identity of CBLSCs and aid in 
verifying their authenticity.  
 
FIGURE   4.23.      Morphology of Cardioblast-like stem cells (CBLSCs).  A,  A colony of CBLSCs, selected for 
with G418. The morphology is clearly distinct from a colony of ESC-line AB2.2 (B), exhibiting a more rounded-up 
shape and no sharp circumference. The cells appear to be less well attached to feeder cell layers and to each other. 
Scale bar = 50 µm. 
 
10 days after seeding, 12 colonies were picked and replated on a 96-well plate. Of these, 11 
could successfully be expanded on feeder cell layers (termed “A3”, “B3”, “C3”, “D3”, “E3”, 
“F3”, “G3”, “H3”, “A5”, “B5” and “D5”). Currently, the properties of clones G3, H3 and B5 are 
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under investigation. In regard to growth rate, there seems to be no significant difference amongst 
each other or between them and ESCs of the line AB2.2. The in vitro differentiation experiment 
has successfully been reproduced for each clone, with M-LIF and D-LIF treated cells showing 
beating cells after approximately two weeks. Analysis of gene expression has revealed that the 
cardiospecific genes NKX 2.5, MEF 2C, and Tropomyosin α are highly upregulated in these 
cells. Aggregates have been produced and cultured analogously to embryoid bodies. These 
“cardiac bodies” form beating cardiomyocytes, although with a significant time-lag in respect to 
embryoid bodies. Interestingly, they have also been shown to generate a large amount of smooth 
muscle cells, demonstrating that CBLSCs are capable of producing mesodermal cells other than 
cardiomyocytes. 
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5 Discussion 
Cardiovascular disease and resulting heart failure represent one of the most frequent causes of 
death in western civilization. Upon heart failure, functional cardiomyocytes are lost, which 
cannot be fully replaced by the recently described cardiac stem cells (Beltrami et al., 2003; 
Urbanek et al., 2005). The identification of factors, which could activate these quiescent cardiac 
stem cells and cause them to differentiate into functional cardiomyocytes would be an important 
step towards finding new therapies for the treatment of heart diseases. 
Previously, it has been suggested that M-LIF may induce increased proliferation and longevity of 
cardiac progenitor cells. Here, we provide evidence that not only M-LIF, but D-LIF as well, can 
be utilized as factors to trigger expansion of cardiac stem cells and indirectly induce 
differentiation into functional heart cells in vitro. 
 
5.1 Production and purification of M-LIF and D-LIF 
D-LIF and M-LIF were produced in insect cells using the baculovirus system in order to obtain 
these cytokines in their postranslationally modified forms. LIF is known to be heavily modified 
by glycosylation (Sasai et al., 1998), which could very likely influence biological activity and/or 
function of this protein. Since vectors encoding D-LIF and M-LIF, respectively, contained 
coding sequences for carboxy-terminal 6xHIS-tags, Ni++-affinity chromatography was used for 
purification. Western blot and deglycosylation analyses proved that LIF had been successfully 
expressed and purified in their glycosylated forms ranging from a MW of 30 – 40 kD, which 
could be reduced to a single band at approximately 23 kD upon deglycosylation. An 
unglycosylated form of LIF at a MW of approximately 19 kD was also found. Since D-LIF and 
M-LIF have calculated masses of 22.29 kD and 22.16 kD, respectively, and 6 histidines amount 
to a MW of 0.84 kD, the 23-kD form was assumed to be LIF in its full-length version. 
To investigate the amino-termini of D-LIF and M-LIF, mass spectrometry analysis was 
performed with several enzymes, revealing that amino acids upstream of H39/36 could not be 
detected in the 19 kD-form, and amino acids upstream of S24/21 could not be detected in the 23 
kD-form. This suggests that the entire leader sequence upstream of amino acid 24/21 is removed 
in the mature version of both isoforms of LIF, as has been proposed in a previous study (Rathjen, 
1990).  
However, several findings cast doubt on this conclusion. First, no cleavage site for enzymes 
could be identified directly upstream of S24/21, raising the question as to how these amino acids 
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should actually be removed by posttranslational means. Second, the carboxy-termini could not 
be completely detected in any of the performed mass spectrometry analyses although they were 
most certainly present, due to the fact that the HIS-tags adjacent to them could be detected via 
Western blot analysis. Hence, since amino acids were incompletely detected at the carboxy-
terminus, the same could apply to amino acids at the amino-terminus. Third, if mass 
spectrometry results for the amino-termini of both analyzed forms are to be believed, LIF should 
only be 1.21 kD heavier than the truncated variant of LIF, as this is the number calculated for the 
stretch of amino acids ranging from S24/21 to H39/36. However, SDS-PAGE analysis revealed a 
far greater difference in weight of approximately 4 kD, a number that coincides almost perfectly 
with the MW of the combined first 38/35 amino acids present in full-length LIF, which was 
calculated to be 3.97 kD in the case of D-LIF, and 3.85 kD in the case of M-LIF. And last but not 
least, if the leader sequence is indeed missing, then why was LIF found at 23 kD? In the absence 
of the first 23/20 amino acids LIF containing a HIS tag should have a combined mass of no more 
than 20.7 kD.  
These considerations lead us to believe that the full-length amino-termini may very well be 
present, in spite of them not being detected by mass spectrometry. 
 
5.2 M-LIF and D-LIF promote self-renewal in embryonic 
stem cells  
Biological activity of recombinantly produced M-LIF and D-LIF was first tested on embryonic 
stem cells (ESCs). Results obtained from an alkaline phosphatase assay (AP assay) revealed that 
both M-LIF and D-LIF have the ability to keep ESCs in an undifferentiated state. Glycosylation 
apparently has no effect in terms of self-renewal capacity, since recombinant LIF produced in 
E.coli had the same effect as the glycosylated versions expressed in Sf9 cells. ESCs in the 
absence of LIF showed a high degree of differentiation. A small amount of undifferentiated cell 
colonies could also be observed in this case, which can be explained by the fact that ESCs have 
the ability to support each other in terms of self-renewal when in close contact. Interestingly, 
protein extract isolated from uninfected Sf9 cells promoted self-renewal of ESCs to a slight 
degree, when compared to ESCs that had been left untreated. This can be ascribed to interleukins 
of insect cell origin that had not been completely removed in the purification process. The effect 
was however low, when compared to that induced by purified extract containing M-LIF and D-
LIF, respectively. 
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The AP assay conducted in this study proved that LIF had been successfully expressed and 
purified, since biological activity could be detected to a comparable degree to that of LIF 
produced in E.coli. 
 
5.3 M-LIF and D-LIF retard mesoderm formation in 
embryoid bodies  
After biological activity of M-LIF and D-LIF had been confirmed, their effect was tested on ESC 
derived embryoid bodies (EBs). An EB is an in vitro model proposed to recapitulate early 
embryogenesis. In EBs, mesoderm formation takes place between 2 and 5 days after aggregation 
(Leahy et al., 1999) and cardiomyocytes begin to beat rhythmically between 6 and 7 days after 
aggregation (Weitzer et al., 1995). In the presence of glycosylated M-LIF and D-LIF, mesoderm 
formation was shown to be retarded. When added on day 7, appearance of rhythmically beating 
cardiomyocytes was delayed by 2 days in the case of D-LIF and by 3 days in the case of M-LIF, 
respectively. The amount of beating cells was consistently lower in the presence of glycosylated 
LIF through days 7 to 11, with M-LIF being marginally more inhibiting than D-LIF.  
Surprisingly, treatment with unglycosylated LIF showed different results. Inhibition of 
mesoderm formation could be observed neither when added on day 5, nor on day 7, after 
aggregation. Quite the contrary, unglycosylated LIF even seemed to promote mesoderm 
formation when added on day 7, with 89% of EBs containing beating cells on day 10 compared 
to only 53% in untreated cells. These findings are similar to previously published data in which 
unglycosylated LIF was shown to positively influence cardiomyocyte formation in EBs when 
administered after day 4 (Bader et al., 2000). Thus, glycosylation appears to have an impact on 
differentiation, but not on self-renewal (see 5.2). 
 
5.4 Glycosylated M-LIF and D-LIF promote contractility 
and proliferation of primary cardiomyocytes  
It has been reported that primary cardiomyocytes (pCMCs) show increased proliferation and 
longevity when grown on lif -/-m-lif ect parietal endoderm (PE), but not when grown on               
lif -/-d-lif ect PE (Pasteiner, 2006). This suggests that M-LIF significantly promotes proliferation 
and longevity, as opposed to D-LIF. To affirm this conclusion, several experiments were 
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performed in which pCMCs were treated with recombinantly produced M-LIF and D-LIF, 
respectively, in the absence of feeder cells. The data of these experiments reveal a certain degree 
of increased proliferation and contractility, however, no appreciable difference between the 
effect of M-LIF and D-LIF could be found. Furthermore, longevity did not seem to be markedly 
increased in the presence of M-LIF and D-LIF, respectively. These findings can in part be 
explained by the lack of feeder cells, which certainly produce a large number of growth and 
survival factors aside from LIF that serve to aid in proliferation and longevity. The reason why 
M-LIF unexpectedly did not show more beneficial results than D-LIF is less clear. Possibly, M-
LIF indirectly stimulated pCMCs in the previously mentioned study by triggering the release of 
other factors from the feeder cells.  
A difference could, however, again be found between the effect of glycosylated and 
unglycosylated LIF, with the latter not stimulating proliferation and contractility in two 
experiments and only slightly in one of the three performed experiments. This does correlate 
with previous findings (Pasteiner, 2006). As observed in the case of EB formation, glycosylation 
seems to play a role in biological activity of LIF. 
 
5.5 The influence of M-LIF and D-LIF on gene expression 
of primary cardiomyocytes 
To investigate changes caused by M-LIF and D-LIF, respectively, on the level of gene 
expression in pCMCs, the mRNA of several cardio-specific marker genes was analyzed by semi-
quantitative RT-PCR. pCMCs treated with D-LIF exhibited decreased gene expression for all 
analyzed cardiac marker genes after 10 days, when compared to cells treated with M-LIF. The 
anti-apoptotic gene BCL-XL was found to be marginally upregulated on day 10 as well as day 6 
in cells treated with M-LIF. This finding is in concordance with results obtained from M-LIF and 
D-LIF overexpressing PE, respectively (Pasteiner, 2006). Upregulation could, however, not be 
demonstrated for any of the other tested marker genes.  
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5.6 M-LIF and D-LIF promote proliferation and 
differentiation of cardioblast-like stem cells  
M-LIF and D-LIF both induced a significant degree of proliferation in cardioblast-like stem cells 
(CBLSCs). Since LIF is known to have a positive influence regarding proliferation of ESCs, 
these findings were expected. What is more intriguing is LIF’s influence on differentiation. 
Approximately 12 days after treatment for 4 days with M-LIF and D-LIF, respectively, and 
subsequent replating at a dilution of 1:50 (approximately 6x104 cells per 6-well plate well), a 
monolayer of fully differentiated cells could be observed. Since a large number of rhythmically 
beating aggregates was observed it is clear that heart cells had formed. Wells containing 
untreated cells, on the other hand, seemed to have remained for the most part undifferentiated, as 
most cells were small and round and no contractility was observed.  
The above findings indicate that LIF directly leads to a surge in proliferation and indirectly leads 
to differentiation upon removal. These seemingly adverse functions may be explained by the 
previously described pathways (Cavaleri et Schöler, 2004), one stimulating proliferation via 
phosphorylation of STAT3 and the other leading to the expression of differentiation-inducing 
genes via the SHP-2/Ras pathway. How LIF can stimulate differentiation indirectly, however, is 
unclear. Perhaps the signal for differentiation is outweighed at first by the signal for proliferation 
induced by LIF and only becomes active after LIF is removed, since this signal may be longer-
lasting. Another possibility could be that the formation of differentiated heart cells is merely 
dependant on the number of seeded cells which was naturally higher for cells that had been 
treated with LIF. Initial density was indeed found to have an impact on differentiation, since 
fewer beating cells were observed in wells containing cells that had been seeded at a dilution of 
1:100 (approximately 3x104 cells) after LIF treatment. This, however, would not explain the 
morphological differences found between untreated cells and cells treated with LIF. In any case, 
both M-LIF and D-LIF have been found to ultimately serve as cues for the production of beating 
heart cells from undifferentiated CBLSCs in as little as 16 days. 
Interestingly, beating cells had also formed in wells treated with the control extract of uninfected 
Sf9 cells. However, these cells had not formed a monolayer and were small, round and tightly 
packed, quite similar to the appearance of cardiomyocytes found in EBs. Furthermore, these cells 
contracted at a considerably quicker pace than LIF treated cells, averaging approximately 80 
bpm, as opposed to 50 bpm. Again, there is a parallel to EBs, since cardiomyocytes in wild-type 
EBs are known to contract at a mean frequency of 80 bpm (Hofner et al., 2007).  
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Perhaps these parallels indicate that CBLSCs treated with the control extract did not differentiate 
to the same degree as those treated with LIF, giving rise to cardiomyocytes of an earlier 
developmental stage. Cells initially treated with LIF, on the other hand, seemed to have 
completely differentiated into viable heart cells. 
 
5.7  CBLSCs represent an autonomous stem cell line of 
somatic origin 
The CBLSCs used in the former experiments had been isolated from neonatal mouse hearts in 
co-culture with ESCs (Weber, 2006). These cells have a morphology quite similar to that of 
cardioblasts and exhibit stem cell-like behaviour, hence the name “cardioblast-like stem cells”. 
They are larger than ESCs and appear to attach less well to feeder cell layers and to one another. 
Since knowledge of the exact nature of these cells is still very incomplete, several experiments 
were performed in order to further characterize them. 
First, the growth rate of CBLSCs was analyzed. After generation of a growth curve during the 
period of 12 days, a doubling time (DT) of 29.9 h was calculated. Doubling times for ESCs have 
been reported to lie within the range of 22 and 24 hours, thus, the growth rate of CBLSCs seems 
to be markedly slower than that of ESCs. Second, karyotyping was performed. Since CBLSCs 
had been isolated in co-culture with ESCs, it seems conceivable that they could have been 
generated by a fusion event. After observation of chromosome spreads, cells were found to be 
diploid, ruling out the possibility of CBLSCs constituting cells generated by fusion of heart cells 
and ESCs. Third, single-cell cloning was conducted. The most critical parameter in the definition 
of stem cells is their clonality which is the ability of single undifferentiated cells to self-renew, 
proliferate, and differentiate to produce mature progeny cells (Wagers and Weissman, 2004). 
Therefore, CBLSCs must be subclonable at a single cell level, in order to be justifiably 
considered as stem cells. Here, eleven colonies of CBLSCs were successfully subcloned under 
selection of G418, in effect ruling out the possibility of CBLSCs constituting a mixed culture of 
somatic and embryonic stem cells. These test results, in addition to the observations made 
regarding morphology, affirm the notion of CBLSCs representing an autonomous, somatic stem 
cell line. 
In recent developments, the subclones have been shown to exhibit similar growth rates. In vitro 
differentiation has been successfully reproduced and cardiospecific marker genes, such as NKX 
2.5, MEF 2C and Tropomyosin α have been shown to be highly upregulated in differentiated 
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cells. Furthermore, aggregates analogous to embryoid bodies (coined “cardiac bodies”) have 
been produced, leading to the formation not only of cardiomyocytes, but a large number of 
smooth muscle cells, as well. This indicates that CBLSCs are capable of producing mesodermal 
cells besides cardiomyocytes and perhaps even cells of distinct lineages, similar to the findings 
published by other groups (Krause et al., 2002; Poulsom et al., 2002; Beltrami et al., 2007). 
 
5.8 Conclusion 
In this study, glycosylated recombinant M-LIF and D-LIF, respectively, have been found to, 
first, cause drastic proliferation of cardiac progenitor cells, and second, indirectly serve as cues 
for differentiation into heart cells in vitro. No significant differences concerning these abilities 
could be observed between either isoform when administered in recombinant form. Perhaps the 
short amino-terminal peptide MRCRIV present in M-LIF merely serves as a sorting signal that is 
capable of targeting polypeptides to the extracellular matrix, as has been previously suggested 
(Rathjen et al., 1990). A difference between glycosylated and unglycosylated LIF regarding 
biological activity was observed, but only regarding differentiation. 
The above findings imply that recombinant glycosylated M-LIF and D-LIF, respectively, can be 
utilized as factors to trigger expansion of cardiac stem cells and induce differentiation into 
functional heart cells in vitro. Since expansion and self-renewal of cardiac progenitor cells seem 
to be the primary function of LIF, other factors such as Bmp2 - a member of the TGF-ß growth 
factor family which has been shown to actively induce differentiation of heart cells (Behfar et al., 
2002) – could perhaps be used in combination with either M-LIF or D-LIF to generate vast in 
vitro cultures of heart cells quickly and efficiently, which may ultimately be used for cell therapy 
of the diseased heart. 
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